

Index

ABCD rule, 180–181	acetaminophen, 313, 752–754	acute myocardial infarctions
ABCD2 rule, 90, 180–181	order sets, 733, 735	(AMIs), 23, 108, 413
abdominal aortic aneurysm,	oxycodone with, 735	adenosine, 127–129
314	toxicology	adenosine triphosphate (ATP),
abdominal pain, 309	admission criteria, 323–324	139–140, 194–195
clinical protocols, 514	contraindications to admission,	adenyl cyclase, 139–140
diagnostic approach formulating,	323–324	ADHF. <i>See</i> acute decompensated
263	discharge criteria, 324	heart failure
discharge criteria, 514	management, 324	Administrative policies
disposition criteria, 301, 514	ACOs. <i>See</i> Acute Care	advanced practice providers
evidence basis, 449–450, 462–463	Organizations	(APPs) in the observation
exclusion criteria, 301, 306, 309,	ACS. <i>See</i> acute coronary syndrome	unit, 6
514	action potential, 202, 205–206	care coordinator, 570–571 (See
gastroparesis, 310	acuity metrics, 52	also case manager)
in geriatric observation medicine,	acuity ranking, 38	charge nurse, 571–572
306	Acute Care Organizations (ACOs),	change of shift, 572
in IBD, 310	77, 382, 478	communication board, 572–573
inclusion criteria, 306, 309, 514	CMS on, 92	continuing (ongoing) care of
initial diagnostic approach, 263	components of, 93–94	patients in the observation
inpatient admission, 514	defining, 92–93	unit, 573–574
management, 310	development of, 395	data base for the observation unit,
observation, 265–266	health care industry and, 92	574–575
observation unit interventions,	HMO compared with, 92–93	delegation of care in the
514	Medicare on, 93	observation unit, 573
order sets	observation medicine and, 93	disposition of OU patients:
allergies in, 602–603	observation units and, 93–94	admission to inpatient floor
medications, 603–604	skeptics on, 92–93	from OU, 576
nursing interventions in, 602	acute care staffing, 28	disposition of OU patients:
respiratory interventions in,	acute coronary syndrome (ACS), 98,	discharge from OU, 576–577
603	101–102, 124, 127, 410	documentation: nursing, 577–579
vital signs in, 602	diagnosis, 103	documentation: physician,
pediatric observation, 301–302	disposition, 103	579–580
presentation of, 309	German observation medicine,	medical director of observation
risk management, 46	413	unit, 581–582
threshold, 263–264	immediate management, 103	metrics for the observation unit,
abdominal trauma	acute decompensated heart failure	582–584
evidence basis, 454–455	(ADHF), 107	mission statement, 585
order sets, 713–715	acute hemolytic transfusion reaction	nurse manager for the
medications, 714–715	(AHTR), 255	observation unit, 585–586
ABN. <i>See</i> Advanced Beneficiary	acute intoxication, 515–516	nursing scope of patient care
Notice	acute low back pain, 314–315	(nursing services provided to
absence seizures, 201	Acute Medical Units (AMUs), 95	OU patients), 586–588
ACA. <i>See</i> affordable care act	guidelines, 95	nursing responsibilities, 588–589
ACC. <i>See</i> Alternate Care Center	observation medicine and, 95–96	nursing and ancillary staffing
Accelerated Diagnostic Treatment	outcomes, 96	for the observation unit,
Center (ADTC), 512	size of, 96	589–590
access to care, 81–82	standards for, 95	organizational structure of the
ACE. <i>See</i> angiotensin-converting	variability in, 95	unit, 590–591
enzyme	Acute Medicine, 95–96	patient criteria for placement in
ACEP. <i>See</i> American College of	development of, 95	the OU: patients meeting
Emergency Physicians	patient safety in, 95	specific clinical criteria, 580

Index

- Administrative policies (cont.)
 patient criteria for placement in
 the OU: patients not meeting
 specific clinical criteria, 580
 patients placed in the observation
 unit (observation status),
 574, 576–577, 583, 588, 590,
 628, 745
 patient selection for the
 observation unit, (patients
 placed in the observation
 unit) 258–260
 patients with infectious diseases,
 580, 583
 performance improvement
 (continuous quality
 improvement), 48, 292
 physician availability, 6
 physician responsibility for the
 observation unit, 575
 physician staffing (coverage) for
 the observation unit, 5, 39
 quality indicators for the
 observation unit, 582
 residents/fellows in the
 observation unit, 578
administrative protocols, 513 (See
 also Administrative policies)
admission criteria. *See also* exclusion
 criteria; inclusion criteria;
 inpatient admission, clinical
 protocols
 acetaminophen toxicology, 323–324
 benzodiazepines toxicology, 324
 bupropion toxicology, 325
 carbon monoxide toxicology, 326
 crotalid envenomation toxicology,
 328
 HF, 111
 Latrodectus mactans
 envenomation, 328
 neuroleptics toxicology, 327
 opioids toxicology, 326
 pediatric observation, 302
 SCD, 246–247
 sulfonylurea toxicology, 325
 VOC, 246–247
ADTC. *See* Accelerated Diagnostic
 Treatment Center
adult generic order set, 748–751
Advanced Beneficiary Notice
 (ABN), 364–365, 372
Advanced Practice Clinicians
 (APC), 5–6, 33–34 (See also
 advanced practice
 practitioners (APP), mid-
 level providers, nurse
 practitioners, physician
 assistants)
 EDOU, 35
 responsibilities of, 6
 in stakeholder analysis, 384
Advanced Practice Providers (APP),
 5–6
Advanced Trauma Life Support
 (ATLS), 318–319
aerosols, 606, 612, 631
Aetna, 370–371
AF. *See* atrial fibrillation
Affordable care act (Obamacare),
 92
Agency for Healthcare Research and
 Quality (AHRQ), 107
age-related observation, 478–479
 future of, 484
 geriatric patients, 483
 discussion, 483
 inclusion criteria, 301
 methodology, 479
 pediatric results, 479–482
 costs in, 479–482
 dehydration, 481
 discussion, 482–483
 morbidity in, 481
 readmission rates, 481
 reoccurrence rates, 481
 return visits, 481
 satisfaction, 482
 in United States, 484
AHA. *See* American Heart
 Association
AHRQ. *See* Agency for Healthcare
 Research and Quality
AHTR. *See* acute hemolytic
 transfusion reaction
AICA. *See* anterior inferior
 cerebellar artery
albuterol, 146–147, 740, 759
alcohol, 337
alcoholism, 46–47
allergic reaction
 in abdominal pain order set,
 602–603
 clinical protocols, 514–515
 contrast, 747, 760–761
 discharge criteria, 515
 disposition criteria, 515
 exclusion criteria, 514
 inclusion criteria, 514
 inpatient admission, 515
 observation unit interventions,
 515
 rattlesnake bites, 556
 timeframe, 515
alpha2-adrenergic agonists,
 657
altered mental status
 clinical protocol, 515–516
 disposition criteria, 516
 exclusion criteria, 306, 515
 geriatric observation medicine,
 305
 inclusion criteria, 305, 515
 inpatient admission, 516
 management, 305–306
 observation unit interventions,
 515–516
 order sets, 608–610
 medications for, 609–610
 patient identification, 333–334
Alternate Care Center (ACC),
 340–341
alternative care facilities
 in disasters, 339–341
 setup of, 341
 staffing, 341
aluminum hydroxide, 746
Alvarado score, 404
AMA. *See* American Medical
 Association
Ambulatory Payment Classification,
 24–25, 360
American College of Cardiology, 25,
 98, 107, 114–115
American College of Emergency
 Medicine, 32
American College of Emergency
 Physicians (ACEP), 23–24,
 58, 336
 literature classification schema,
 469, 503
American College of Nuclear
 Cardiology, 25
American Heart Association
 (AHA), 25, 98, 107, 114–115
American Medical Association
 (AMA), 24
 on medical necessity, 371
aminoglycosides, 281
aminophylline, 140
amiodarone, 115
AMIs. *See* acute myocardial
 infarctions
amoxicillin, 754
 with clavulanic acid, 754–755
 order sets, 735
ampicillin, 151, 755
 order sets, 735
 with sulbactam, 735, 755
AMUs. *See* Acute Medical Units
analgesics order sets, 733–735
ancillary staffing, 31–32
 background, 589
 EDOU, 35
 objectives, 589
 policies, 589
ancillary testing, 394
angioedema, 606–607
 clinical protocols, 514–515
 discharge criteria, 515
 disposition criteria, 515
 inclusion criteria, 514
 inpatient admission, 515
 observation unit interventions,
 515
 order sets, 604–605

- nursing interventions, 605
- respiratory interventions, 605
- timeframe, 515
- angiotensin receptor blocker (ARB), 82, 236–237
- angiotensin-converting enzyme (ACE), 82, 236–237
- inhibitors, 657
- for HF, 110–111
- antacids, 604, 639, 652, 746
- anterior inferior cerebellar artery (AICA), 220
- Anthem, 370–371
- antianginal agents, 623
- antibiotic therapy, 721
- intravenous, 612, 620, 761
- oral, 612, 620, 631
- order sets, 735–737
- SSTIs, 261
- antibiotic treatment, 146–147
- acute bronchitis 511
- cellulitis, 257 (See also skin/soft tissue infections, SSTI)
- chronic bronchitis, 147
- COPD, 147
- Pneumonia, 151
- anticholinergics, 146–147
- anticoagulation, 116, 615, 703–704
- bridging, 160
- in ED, 173
- excessive, 174–175
- observation care, 177
- for PE, 169
- for stroke, 185
- vitamin K reversal, 175
- antidiabetic agents, 637
- antiemetics order sets, 737–738
- antiepileptic drugs, 206
- antihistamines, 651
- antiplatelet agents, 615, 623
- antipyretics, 733–735
- antireflux medications, 604
- antithrombotic agents, 704
- antitussives, 738–739
- anxiety, 481
- defined, 333
- anxiolytics, 757
- aortic dissection, 98, 314
- APC. *See* Advanced Practice Clinicians
- apical pneumothoraces, 155
- exclusion criteria, 548–549
- inclusion criteria, 548
- APP. *See* Advanced Practice Providers
- appendicitis, 264–265
- appropriate level of care, 23
- ARB. *See* angiotensin receptor blocker
- armamentarium, 140
- arteriovenous malformation (AVM), 201
- ASPECT study, 103
- aspirin, 752
- order sets, 733
- for stroke prevention, 184
- Assistant Secretary for Preparedness and Response (ASPR), 339–341
- asthma
- clinical protocols, 511–512
- ,516–517
- cost of care of, 138, 480
- death rates, 138
- definition, 138
- discharge criteria, 517
- disposition criteria, 140–141, 517
- in emergency department, 138
- evidence basis, 445–447
- exclusion criteria, 138–140, 516
- inclusion criteria, 138–140, 516
- inpatient admission, 517
- medications, 139–140, 759
- observation unit interventions, 516–517
- order sets, 611–613
- medications, 612–613
- in pediatric patients, 480
- prevalence of, 138
- risk factors, 141
- risk management, 46
- severity, 139
- in Singapore observation medicine, 405
- treatment in observation unit, 139
- treatment strategies, 138
- ATLS. *See* Advanced Trauma Life Support
- atonic, 201
- atorvastatin, 741–742
- ATP. *See* adenosine triphosphate
- atrial fibrillation (AF), 473
- clinical protocols, 517–518
- demographics and, 114
- discharge criteria, 517
- disposition criteria, 517–518
- electrophysiology, 114–115
- evidence basis, 461–462
- exclusion criteria, 118–119, 517
- inclusion criteria, 118–119, 517
- inpatient admission, 517
- management of, 115–117
- observation, 119
- observation unit interventions, 517
- order sets
- cardiac medications, 615
- nursing interventions, 614
- respiratory interventions, 614
- vital signs, 613
- paroxysmal, 114–115
- pathophysiology, 114–115
- prevalence of, 114
- Australasian observation wards
- culture, 407
- diagnostic group guidelines, 407
- ED proximity, 406
- Emergency Physician in, 406
- exclusion criteria, 406–407
- impact of, 407
- inclusion criteria, 406–407
- management plans, 407
- minimum requirements, 406–407
- model of care, 406
- time limits, 407
- aviation flight team model, 48
- AVM. *See* arteriovenous malformation
- azithromycin, 755
- order sets, 736
- baby boomers, 483–484
- back pain
- acute low, 314–315
- clinical protocols, 518
- discharge criteria, 518
- disposition criteria, 518
- exclusion criteria, 518
- inclusion criteria, 518
- inpatient admission, 518
- observation unit interventions, 518
- order sets, 616–618
- medications, 617–618
- barium enema, 481
- bathroom facilities, 39
- benchmarks, CQI, 53–54
- beneficiaries, 767
- beneficiary notices, 364–365
- benign paroxysmal positional vertigo (BPPV), 212, 215–218
- benzodiazepines
- order sets, 739
- toxicology
- admission criteria, 324
- contraindications to admission, 324
- discharge criteria, 324
- management, 324
- reversal, 325
- best practices
- EDOU, 478
- operations, 24
- reimbursement and, 356–357
- beta adrenergic agonists, 146
- beta blockers, 656–657
- beta-blockers, 115, 131
- bicarbonate therapy, 228
- biomarkers, 108
- bipolar disorder, 333
- bisacodyl, 746
- bisphosphonate therapy, 239
- Blatchford system, 267–268
- bleeding, 173
- major, 174–175

Index

- bleeding (cont.)
 - minor, 174–175
 - risks, 174–175
- Blue Cross Blue Shield, 378
- BNP. *See* B-type natriuretic peptide
- bowel evacuant, 639
- BPPV. *See* benign paroxysmal positional vertigo
- bradykinin B2 receptor antagonist, 606
- bridging anticoagulants, 160
- British Thoracic Society (BTS), 154
- bronchodilation, 139–140
- Bronchitis, 553
- Brugada syndrome, 124
- BTS. *See* British Thoracic Society
- B-type natriuretic peptide (BNP), 108, 144–145, 167, 419
- BUN, 227
- bupropion toxicology
 - admission criteria, 325
 - contraindications for admission, 325
 - discharge criteria, 325
 - management, 325
- business model
 - cost savings in, 391
 - efficiency, 394–395
 - finances in, 392–394
 - first steps, 391–392
 - forecasting, 392
 - future trends, 395
 - healthcare services, 391
 - needs for, 391
 - operational oversight, 395
 - quality in, 392–394
 - stakeholder analysis, 382–384
 - SWOT in, 382
- CI esterase inhibitor concentrate, 606
- CAD. *See* coronary artery disease
- calcitonin gene-related peptide (CGR), 193
- calcium, 237
- calcium channel blockers, 115, 131, 657
- calcium oxalate, 274
- call back programs, 6
- CALs. *See* Coding Analyses for Labs
- cAMP. *See* cyclic adenosine monophosphate
- Canadian Registry, 268
- CAP. *See* community acquired pneumonia
- CARASI, 150
- carbon monoxide toxicology
 - admission criteria, 326
 - contraindications to admission, 326
 - discharge criteria, 326
 - management, 326
- cardiac imaging, 183–184
- cardiac magnetic resonance imaging (CMR), 103
 - characteristics, 130
 - stress, 130
- cardiac markers, 101–102
- cardiac medications
 - chest pain, 623–624
 - congestive heart failure, 626–628
 - hypertension, 656–658
 - order sets, 740–741
- cardiac studies, 60
 - in observation unit, 40
 - order sets, 732
- cardiac tamponade, 98
- cardio/pulmonary department, patient recognition, 37
- cardioversion, 115
- care coordination, 367
- carotid artery duplex ultrasound, 183
- carotid endarterectomy (CEA), 185
- CARSI, 150
- case management, 367, 395, 571
 - background, 570
 - certification, 570–571
 - disposition, 577
 - job description, 570
 - objectives, 570
 - training, 570
- Case Management Society of America (CMSA), 367
- casualty transport systems (CTS), 340–341
- cauda equina syndrome, 314
- CDC. *See* Center for Disease Control
- CDR. *See* clinical decision rules
- CDU. *See* Clinical Decision Unit
- CEA. *See* carotid endarterectomy
- cefazolin, 755
 - order sets, 736
- ceftriaxone, 755
 - order sets, 736
- cellulitis, 73–74, 257
 - clinical priorities, 518–519
 - discharge criteria, 519
 - disposition criteria, 519
 - evidence basis, 454
 - exclusion criteria, 518–519
 - inclusion criteria, 518
 - inpatient admission, 519
 - observation unit interventions, 519
 - order sets, 619–621
 - medications, 620–621
- census
 - daily, 40–41
 - hourly, 40–41
 - observation unit, 40
 - staffing, 40–41
- Center for Disease Control (CDC), 580
- Center for Health Policy Research, 92
- Centers for Medicare and Medicaid (CMS), 13–14, 25, 76, 355, 363, 430–431, 766
 - on ACOs, 92
 - APC 8002–8003, 386
 - CERT development by, 373
 - claims data, 76
 - contracts with QIOs, 20
 - InterQual licensed by, 370
 - on medical records, 357
 - on outpatient observation services, 20
 - readmissions rates, 78
 - tertiary care hospitals and, 63
- central nervous system (CNS)
 - anatomy, 192–193
 - hyperexcitation, 323
 - in pain pathophysiology, 196
 - shunt, 222
 - discussion, 222
 - exclusion criteria, 222
 - inclusion criteria, 222
 - management, 222–223
 - outcome, 223
- central sensitization, 194–195
- cephalexin, 755
 - order sets, 736
- cephalosporins, 281
- cerebral edema, 228
- cerebrospinal fluid (CSF), 197
- cerebrovascular accident (CVA), 201
- CERT. *See* Comprehensive Error Rate Testing
- cetirizine, 740, 757
- CFR (See Code of Federal Regulations)
- CGR. *See* calcitonin gene-related peptide
- CHADS2 score, 116
- change of shift, 575
 - background, 572
 - objectives, 572
 - policy, 572
- charge nurse
 - additional requirements of, 572
 - certification, 572
 - job description, 571
 - objectives, 571
 - reporting structure, 572
 - training, 571
- CHEER. *See* Chest Pain Evaluation in the Emergency Room
- CHEOPS. *See* Children’s Hospital of Eastern Ontario Pain Scale
- CHEPER. *See* Chest Pain Evaluation Registry
- chest pain, 27–28, 88, 98–99, 127, 520
 - cardiac markers, 101–102

- causes of, 98
 - CK-MB and, 102
 - Clinical Protocols, 511–512
 - costs of, 127
 - CQI, 104
 - discharge criteria, 520
 - disposition, 520
 - electrocardiogram for, 101
 - evidence basis, 430–431, 460
 - exclusion criteria, 100, 519
 - inclusion criteria, 100, 519
 - LOS and, 98–99
 - myoglobin and, 102
 - observation unit, 100–101
 - interventions, 519
 - observation usage rate, 89
 - order sets, 622–624
 - cardiac medications, 623–624
 - OU, 31
 - pathophysiology, 99
 - provocative stress test and, 103
 - review of admissions, 374
 - risk management, 46
 - risk scores, 100
 - risk stratification, 99–100
 - troponin and, 102
 - units, 127
- Chest Pain Evaluation in the Emergency Room (CHEER), 99
- Chest Pain Evaluation Registry (CHEPER), 98
- chest pain units (CPUs)
 - concept of, 413–415
 - establishment of, 413
 - in German observation medicine, 413, 415
- chest radiographs (CSR), 153
- CHF. *See* congestive heart failure
- children’s hospital
 - emergency medicine in, 302
 - pediatric observation, 300–302
 - research in, 302
- Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS), 312
- chlamydia, 284
- Christmas disease, 254
- chronic bronchitis, 143–144
 - antibiotic treatment, 147
- chronic obstructive pulmonary disease (COPD), 143
 - antibiotic treatment, 147
 - clinical presentation, 144–145
 - definition, 144
 - differential diagnosis, 145
 - discharge criteria, 521
 - disposition, 147, 521
 - ED management, 145
 - evidence basis, 456
 - exclusion criteria, 520–521
 - inclusion criteria, 520
 - inpatient admission, 521
 - mortality, 143
 - observation unit interventions, 521
 - observation unit management, 145–147
 - order set, 630–632
 - medications, 630–632
 - pathophysiology, 143–144
 - predictors of poor outcome in, 145
 - risk factors, 144
 - shortness of breath in, 144–145
 - in Singapore observation medicine, 405
 - stage I, 144
 - stage II, 144
 - stage III, 144
 - timeframe, 521
- chronic pain
 - of malignancy, 315
 - management, 315
- Cigma, 378
- CIGNA, 370–371
- ciprofloxacin, 281
 - order sets, 736
- CK-MB, 102
- clavulanic acid, 735
 - amoxicillin with, 754–755
- clindamycin, 151, 755–756
 - order sets, 736
- clinical care pathways
 - initiation of, 58
 - nurse staffing, 31–32
- Clinical Data Abstraction Center, 20
- clinical decision rules (CDR), 165–166
- Clinical Decision Unit (CDU), 51, 95–96, 268, 512
 - EMU shift from, 422
 - meetings, 53–54
 - rattlesnake bites in, 563
 - staff requirements, 58–59, 68
- Clinical Protocols, 511–512
 - abdominal pain, 514
 - acute intoxication, 515–516
 - allergic reaction, 514–515
 - altered level of consciousness, 515–516, 608–609 (See also altered mental status)
 - altered mental status, 515–516
 - angioedema, 514–515
 - asthma, 511–512, 516–517
 - atrial fibrillation, 517–518
 - back pain, 518
 - cellulitis, 518–519 (See also skin infections, soft tissue infections, SSTI)
 - chest pain, 511–512, 519–520
 - chronic obstructive pulmonary disease (COPD), 511
 - complex, 512
 - deep vein thrombosis (DVT), 158–159, 165, 539 (See also venous thromboembolic disease)
 - dehydration, 521–522
 - dengue, 512
 - diagnoses in, 511
 - diarrhea, 521–522
 - dizziness, 79 (See also vertigo)
 - electrolyte abnormalities, 523–524
 - exclusion criteria, 511
 - extremity infections, 524–525
 - flank pain (See also renal colic)
 - fluctuations in, 512
 - gastrointestinal bleeding, 525–526
 - generic, 526–527
 - headaches, 527–528
 - headaches with a shunt (See also headaches)
 - heart failure, 528–529
 - hematuria, 529
 - HG, 529–530
 - hypercalcemia, 523–524
 - hyperemesis gravidarum
 - hyperglycemia, 530–531
 - hyperkalemia, 523–524
 - hyponatremia, 523–524
 - hypertension, 531
 - hypoglycemia, 529
 - kidney stones (See also ureterolithiasis)
 - low risk pulmonary emboli, 567
 - near syncope, 289
 - overdose, 482
 - pelvic inflammatory disease, 285
 - pharyngitis/peritonsillar abscess, 532
 - pneumonia/acute bronchitis, 675–679
 - pyelonephritis/urinary tract infection (UTI), 404
 - renal colic, 263 (See also flank pain)
 - seizures, 535
 - skin infections (See also cellulitis, skin and soft tissue infections, soft tissue infections, SSTI)
 - sickle cell disease, 535
 - snakebites, 556–559, 560–564
 - soft tissue infections, 257–262, 516
 - spontaneous pneumothorax, 153–157, 546–555
 - SSTI (skin and soft tissue infections) (See also cellulitis, skin infections, soft tissue infections)
 - Syncope/Near Syncope, 536–537, 690–691

Index

- Clinical Protocols (cont.)
Transfusion, 537
transient ischemic attack, 537
trauma – abdominal, 539–540
trauma – isolated chest injury, 716–718
trauma – extremity injury, 722
trauma – head injury, 543
vaginal bleeding, 287–288
vertigo, 522–523 (See also dizziness)
venous thromboembolic disease, 702–704 (See also deep vein thrombosis [DVT], pulmonary emboli [PE])
inclusion criteria, 511
rattlesnake bites, 556–558
specialized, 548
spectrum of disease in, 511–512
substance abuse, 515–516
uncomplicated, 512
vertigo, 522–523
vomiting, 521–522
clinical technicians, 589
clopidogrel, 184
closed unit, 3
clustering, 38
CMR. *See* cardiac magnetic resonance imaging
CMS, 2, 11, 93, 348, 355, 362–363, 370, 379, 383–384, 386. *See* Centers for Medicare and Medicaid Services
CMSA. *See* Case Management Society of America
CNS. *See* central nervous system
codeine, 313
pharmacokinetic properties, 313
promethazine and, 738–739
Code of Federal Regulations (CFR), 370
coding, 348
medical necessity, 386–387
Coding Analyses for Labs (CALs), 372
cohorting, 38
advantages of, 37
Colombian emergency services, 425
color coding, 37
observation unit patient, 37–38
Commission on Professional and Hospital Activities, 370
Comorbidity, 79, 305, 483
Complications, 73, 165, 175, 222
communication
pediatric patients, 291
in risk management, 44
communication boards for patient rooms
background, 572
objectives, 572
policy, 572–573
community acquired pneumonia (CAP)
definitions, 149
disposition, 151
in ED, 149–150
exclusion criteria, 150–151
hospitalization factors, 150–151
inclusion criteria, 150–151
initial management, 149–150
likely organisms in, 151
mortality rate, 149
prevalence of, 149
risk factors, 149–150
treatment, 151
community hospital perspective
observation medicine, 58–59
pediatric observation in, 59
community planning, 344
comorbidities, 20, 73
Compare Worksheet, 15
complex observation, 12–15
compliance oversight, 361
Comprehensive Error Rate Testing (CERT), 19–20
CMS and, 373
development of, 373
improper payment determinations in, 374
compression ultrasound (CUS), 159–160, 167
computed tomography (CT), 413–415, 750, 764
kidney stones, 276
order sets, 672
of syncope, 124
computed tomography angiogram (CTA), 103, 166
TIA, 183
computed tomography coronary angiography (CTCA), 130
characteristics, 131
Condition Code 44, 364
Condition of Participation, 366
congestive heart failure (CHF), 76, 99, 116, 144–145
evidence basis, 451–454
order sets, 625–629
cardiac medications, 626–628
cardiac studies, 626
Consensus Panel, 268
Consumer Price Index, 477
continuing care policies
background, 573
objectives, 573–574
Continuous Quality Improvement (CQI), 520
benchmarks, 53–54
chest pain and, 104
components, 48
costs, 48
goals, 48
observation unit database, 49–50
observation unit documentation, 50–51
observation unit indicators, 53
observation unit metrics in, 51
OU, 48
pediatric observation, 292
contrast allergy, 747, 760–761
copays, 21
COPD. *See* chronic obstructive pulmonary disease
coronary artery disease (CAD), 108
pretest probability, 127–128
coronary artery stenosis, 128–130
correct status, 363–365
cortical spreading depression, 191
corticosteroids, 146, 612, 631
cortisol, 231
CPT. *See* Current Procedural Terminology
CPUs. *See* chest pain units
CQI. *See* Continuous Quality Improvement
crash cart, 40
crashing, 38
C-reactive protein (CRP), 258–259
creatinine, 227, 259
critical care, 354
CroFab, 557
infusing, 556–557
mixing, 556
crotalid envenomation toxicology
admission criteria, 328
antivenom, 329
contraindications to admission, 328
management, 328
croup, 480–481
in pediatric patients, 481–482
CRP. *See* C-reactive protein
cryoprecipitate, 253
CSF. *See* cerebrospinal fluid
CSR. *See* chest radiographs
CT. *See* computed tomography
CTA. *See* computed tomography angiogram
CTCA. *See* computed tomography coronary angiography
CTS. *See* casualty transport systems
culture reports, 6
CURB, 150
Current Procedural Terminology (CPT), 19, 372, 430–431
private payer observation codes, 357
CUS. *See* compression ultrasound
CVA. *See* cerebrovascular accident
cyclic adenosine monophosphate (cAMP), 139–140, 204–206
CYP1A2, 173–174
CYP2C9, 173–174
CYP3A4, 173–174
cystitis, 281

- dabigatran, 116–117
- dalteparin, 743
- database
 - background, 574
 - demographic, 575
 - key elements, 574
 - objectives, 574
 - policy, 574
 - reimbursement, 575
- DCCT. *See* Diabetes Control and Complications Trial
- D-dimer, 166
- deep vein thrombosis (DVT), 159
- discharge criteria, 162
- in EDOU, 161–162
- evidence basis, 460
- exclusion criteria, 162
- inclusion criteria, 162
- management, 161–162
- medications, 703–704
- order sets, 742–743
- outcome, 163
- treatment, 160
- Defendant Physician, 46
- dehydration, 289
 - clinical protocols, 521–522
 - discharge criteria, 522
 - evaluation, 271–272
 - exclusion criteria, 272, 521
 - inclusion criteria, 272, 521
 - inpatient admission, 522
 - intervention, 272
 - management, 272
 - observation unit interventions, 521–522
 - order sets, 633–635
 - medications, 634–635
 - pathophysiology, 271
- delayed hemolytic transfusion reactions (DHTRs), 255
- delirium, 333–334
- dementia, 334
- Demming approach, 48
- demographic variables, 583
 - AF and, 114
 - database, 575
 - readmissions, 81
- dengue fever
 - discharge criteria, 565–566
 - in EDTU, 565
 - exclusion criteria, 565
 - inclusion criteria, 565
 - inpatient admission, 565
- Department of Health and Human Services (DHHS), 366
- Department of Justice (DOJ), 374
- depolarization, 203–204
- depression, 334
 - major, 333
- designated unit, 2–3
- desmopressin, 253–254
- Deutsche Gesellschaft für Kardiologie (DGK), 413
- dexamethasone, 758
- dextromethorphan, 738
- DGK. *See* Deutsche Gesellschaft für Kardiologie
- DHHS. *See* Department of Health and Human Services
- DHTRs. *See* delayed hemolytic transfusion reactions
- diabetes
 - hypoglycemia in, 232
 - order sets, 636–637
 - antidiabetic agents, 637
 - insulin, 636
 - risk management, 46
 - TIA and, 185
 - type 2, 228
 - type I, 228
- Diabetes Control and Complications Trial (DCCT), 231
- diabetes mellitus, 73–74
- diabetic ketoacidosis (DKA), 225, 226
- diagnosis related group (DRG), 78, 373
 - in IPSS, 18–19
 - payment rates, 18–19
- diarrhea, 521–522
- DIC. *See* disseminated intravascular coagulation
- diet, 624
- diffusion weight imaging (DWI), 218
- digoxin, 115
- dihydroergotamine, 643, 646, 744
- diltiazem, 740–741
- diphenhydramine, 739–740, 744, 757–758
- dipyridamole, 127–129
 - for stroke prevention, 184
- direct pulmonography angiography, 167
- direct thrombin inhibitors (DTI), 169
- disasters
 - alternative care facilities, 339–341
 - defined, 339
 - in-hospital surge in, 339
 - inter hospital surge in, 339
 - special needs shelter in, 343–344
- discharge criteria
 - abdominal pain, 514
 - acetaminophen toxicology, 324
 - AF, 517
 - allergic reaction, 515
 - angioedema, 515
 - asthma, 517
 - back pain, 518
 - benzodiazepines toxicology, 324
 - bupropion toxicology, 325
 - carbon monoxide toxicology, 326
 - cellulitis, 519
 - chest pain, 520
 - COPD, 521
 - dehydration, 522
 - dengue fever, 565–566
 - DVT, 162
 - electrolyte abnormalities, 523
 - extremity infections, 525
 - gastrointestinal bleeding, 526
 - generic protocols, 527
 - headaches, 528
 - heart failure, 529
 - hematuria, 529
 - HF, 111
 - HG, 530
 - hyperglycemia, 531
 - hypertension, 531
 - neuroleptics toxicology, 328
 - observation unit, 516
 - opioids toxicology, 327
 - PE, 162
 - planning, 395
 - PSP, 155–156
 - rattlesnake bites, 558
 - sulfonylureas toxicology, 326
 - TIA, 186–187
 - vertigo, 522–523
- disposition criteria
 - abdominal pain, 514
 - AF, 517–518
 - allergic reaction, 515
 - altered mental status, 516
 - angioedema, 515
 - asthma, 517
 - back pain, 518
 - background, 576–577
 - CAP, 151
 - case management, 577
 - cellulitis, 519
 - chest pain, 520
 - COPD, 147, 521
 - discussion, 577
 - electrolyte abnormalities, 523–524
 - extremity infections, 525
 - gastrointestinal bleeding, 526
 - generic protocols, 526
 - headaches, 527–528
 - heart failure, 528–529
 - hematuria, 529
 - HG, 530
 - hyperglycemia, 531–546
 - hypertension, 531
 - nursing responsibilities, 577
 - objectives, 576–577
 - physician documentation, 579–580
 - physician responsibilities, 575, 577
 - procedure, 576–577
 - rattlesnake bites, 558
 - TIA, 186
 - trauma, 321
 - vertigo, 522–523

Index

- disproportionate share hospital (DSH), 18–19
- disseminated intravascular coagulation (DIC), 251–253
- diuretics, 626, 628
 HF for, 110
 order sets, 741
- Dix-Hallpike maneuver, 215–216
- dizziness, 211
 causes of, 220
 classification, 211–212
 differential, 211–212
 history, 211–212
 physical examination, 212–215
- DKA. *See* diabetic ketoacidosis
- dobutamine, 103, 127–129
- docusate, 746
- DOJ. *See* Department of Justice
- dorsal raphe nucleus, 193
- dorsal root ganglion, 195
- double dipping, 387
- DRG. *See* diagnosis related group
- Drug Information Handbook, 513
- DSH. *See* disproportionate share hospital
- DTI. *See* direct thrombin inhibitors
- Duke Treadmill Score (DTS), 128
- DVT. *See* deep vein thrombosis
- DWI. *See* diffusion weight imaging
- dyspnea, 108
- EC. *See* electrical cardioversion
- ECG. *See* electrocardiogram
- echocardiography
 stress, 130
 characteristics, 131
 for syncope, 124
- economical service, 29
- ECOW. *See* emergency center
 observation wards
- ED. *See* emergency department
- EDOU. *See* Emergency Department Observation Unit
- EDTU. *See* Extended Diagnostic Treatment Unit
- education
 indirect medical, 18–19
 introduction of, 66
 observation medicine, 66–67
 patient, 111
 PGY-1, 66
 PGY-2, 66
 required rotations, 66–67
- EF. *See* ejection fraction
- Effectiveness and Safety of Chest Pain Assessment to Prevent Emergency Admission (ESCAPE), 99
- EHR. *See* electronic health record
- ejection fraction (EF), 111
- elderly population, 77. *See also* geriatric patients
- pain management in, 314
- electrical cardioversion (EC), 115
- electrocardiogram (ECG)
 for chest pain, 101
 for STEMI, 101
 stress, 128
- electrocardiographic monitoring, 124
- electrolyte abnormalities, 235
 calcium, 237
 clinical protocols, 523–524
 discharge, 523
 disposition, 523–524
 exclusion criteria, 523
 inclusion criteria, 523
 inpatient admission, 523
 magnesium, 239
 observation unit interventions, 523
 order sets, 705–706
 potassium, 235
 sodium, 240
 timeframe, 523
- electrolyte replacements
 hypocalcemia, 706–707
 hypokalemia, 708
 hypomagnesemia, 710
 hypophosphatemia, 712
- electronic health record (EHR), 395
- electronic medical records (EMR), 426
 checklists, 376
- electronic records, 31
 observation unit database, 50
- electrophysiology
 AF, 114–115
 of syncope, 124
- EM. *See* emergency medicine
- Emergency Advisors, 424
- Emergency Center, 400
- emergency center observation wards (ECOW)
 admission contraindications, 401–402
 admission to, 399–401
 criteria, 401
 diagnostic evaluation, 401
 management procedures, 400–401
 psychosocial needs in, 401
 short term therapy, 401
 in South Africa, 398–399
- Emergency Centers, 398
- emergency department (ED), 300, 766
 anticipated volume, 31
 anticoagulation, 173
 asthma in, 138
 Australasian observation ward
 proximity to, 406
 CAP in, 149–150
 complaints in, 127
- COPD management, 145
- efficiency, 457–458
- evaluation, 38–39
- expansion projects, 31
- metrics, 52
- number of patients in, 583
- OU differentiated from, 64
- patient evaluation, 43
- patient volumes, 72
- pediatric, 40
 increases in visits, 482
 returns to, 295–296
- pneumonia in, 149
- psychiatric patients in, 332
- rattlesnake bite evaluation, 563
- restructuring, 45
- seizures, 200
- in TIA, 182
- toxicologic disorder visits, 323
- transfer times from, 31
- urban community hospital, 60
- waiting rooms, 43
- Emergency Department Observation Unit (EDOU), 33
 admissions, 74
 ancillary staffing, 35
 APCs, 35
 beds, 74
 on best practices, 478
 consultants, 35
 culture, 74
 DVT in, 161–162
 efficiency in, 72
 evidence-based protocols, 72–73
 exclusion criteria, 73
 facilities, 74
 geriatric patients in, 483
 inclusion criteria, 73
 intervention, 73–74
 leadership, 33
 literature, 72
 management, 73–74
 needs, 74
 nurses, 33
 physicians, 33
 population in, 72–73
 space for, 33
- Emergency Medical Treatment and Labor Act (EMTALA), 342
- Emergency Medical Unit (EMU), 421
 CDU shifted to, 422
- emergency medicine (EM)
 in children’s hospitals, 302
 components of, 72
 observation medicine and, 68
 in South Africa, 398
- Emergency Medicine Residents Association, 68
- Emergency Medicine Society of South Africa (EMSSA), 398

- Emergency Operations Center (EOC), 339
- Emergency Physician, 380
 in Australasian OW, 406
 in medical necessity denials, 380
 rights for, 406
- emphysema, 143
- EMR. *See* electronic medical records
- EMSSA. *See* Emergency Medicine Society of South Africa
- EMTALA. *See* Emergency Medical Treatment and Labor Act
- EMU. *See* Emergency Medical Unit
- English Common Law, 45
- enoxaparin, 160–161, 743
- Enterobacter*, 280
- entry criteria, 109–110
- EOC. *See* Emergency Operations Center
- epilepsy, 200
 definition, 201
 pathophysiology, 205–206
 patient evaluation, 207–208
 patient selection, 208
- epinephrine, 231
- Epley maneuver, 216
- erythrocyte sedimentation rate (ESR), 197
- erythromycin, 286
- ESC. *See* European Society of Cardiology
- ESCAPE. *See* Effectiveness and Safety of Chest Pain Assessment to Prevent Emergency Admission
- ESR. *See* erythrocyte sedimentation rate
- eszopiclone, 739
- ethanol, 332
- European Society of Cardiology (ESC), 101–102, 114–115, 167
- evening shift, 40–41
- evidence basis, 430–431
 abdominal pain, 449–450, 462–463
 abdominal trauma, 454–455
 AF, 461–462
 asthma, 445–447
 cellulitis, 454
 chest pain, 430–431, 460
 clinical findings, 505–506
 congestive heart failure, 451–454
 COPD, 456
 criteria for, 471
 critical questions, 468, 472
 downgrading strength, 468–470, 504–505
 DVT, 460
 ED efficiency, 457–458
 future research, 468
 geriatric patients, 486–501
- head injury, 450–451, 463
 level A recommendations, 472
 level B recommendations, 472, 472–473
 level C recommendations, 472
 methodology, 431
 pediatric patients, 486–501
 pneumonia, 456
 results, 431–467
 SCD, 462
 summary, 466–468
 syncope, 447–449
 TIA, 460
 toxicology, 455–456, 463
- excitatory neurotransmitters, 204–205
- exclusion criteria. *See also* admission criteria; inclusion criteria
 abdominal pain, 301, 306, 309, 514
 AF, 118–119, 517
 age-related observation, 477–506
 allergic reaction, 514
 altered mental status, 306, 515
 angioedema, 514
 apical pneumothoraces, 548–549
 asthma, 138–140, 516
 Australasian observation wards, 406–407
 back pain, 518
 CAP, 150–151
 cellulitis, 518–519
 central nervous system shunt, 222
 chest pain, 100, 519
 clinical protocols, 511
 COPD, 520–521
 dehydration, 272, 521
 dengue fever, 565
 DVT, 162
 EDOU, 73
 electrolyte abnormalities, 523
 extended observation, 73
 extremity infections, 524
 falls, 305
 gastrointestinal bleeding, 525
 generic protocols, 526
 geriatric observation medicine, 305
 headaches, 527
 heart failure, 528
 hematuria, 529
 HF, 110
 HG, 529–530
 hyperglycemia, 530
 hypertension, 531
 PSP, 155, 546
 rim pneumothoraces, 551
 seizures, 208
 syncope, 123
 trauma, 319
 upper gastrointestinal bleeding, 267
 vertigo, 522
- exercise
 provocative stress test, 103
 readmissions and, 81
- Extended Diagnostic Treatment Unit (EDTU), 565
- extended observation, 12–15
 comprehensive teams, 77
 cost effectiveness, 76
 exclusion criteria, 73
 financial concerns, 77
 inclusion criteria, 73
 LOS, 73
 management, 73–74
 pathophysiology, 73
 patient discharge, 76
 staff, 77
 trends towards, 76
 unit flow, 76–77
- External Review, 379
- extremity infections
 clinical protocols, 524–525
 discharge criteria, 525
 disposition criteria, 525
 exclusion criteria, 524
 inclusion criteria, 524
 inpatient admission, 525
 observation unit interventions, 524–525
 timeframe, 525
- extremity trauma order sets, 720–722
- facility reimbursement, 24–25, 360–361
 Medicare rates, 360–361
- factor deficiencies, 253
- factor IX deficiency, 254
- factor V Leiden deficiency, 251–252
- factor VIII, 253
 deficiency, 253–254
- factor Xa inhibitors, 703
- factor XI deficiency, 251–252
- factor XIII, 253
- falls, 305
 exclusion criteria, 305
 in geriatric observation medicine, 304
 inclusion criteria, 304
 mechanical, 320
- famotidine, 746, 760
- fast-track patients, 41
- febrile non-hemolytic transfusion reactions (FNHTR), 255
- febrile seizures, 200
- fellowships, 68
- fentanyl, 313, 752–753
 order sets, 733–734
 pharmacokinetic properties, 313
- FFP. *See* fresh frozen plasma
- FI. *See* Fiscal Intermediaries
- fibrinogen deficiency, 253
- financial viability, 24–25

Index

- finger stick glucose determination, 371
- First Level review, 378–379
Medicare, 379
- Fiscal Intermediaries (FI), 15, 373–374
claims appeals, 378
- FISS (See Fiscal Intermediary Standard Systems) flexible staffing, 4
- Fiscal Intermediary Standard Systems fluoroquinolones, 151, 281
- FNHTR. *See* febrile non-hemolytic transfusion reactions
- follow-up phone calls, 82
- fondaparinux, 169, 743
- Fourth Level appeal, 379
- Framingham Study, 115
- French observation medicine, 411
organization, 411
palliative care in, 411
perspectives on, 411
social workers in, 411
- fresh frozen plasma (FFP), 251–253
effectivity, 252–253
warfarin and, 252
- functional physical plant, 24
- Fundacion Cardio Infantil ED, 424
care at, 424
challenges in, 425
Pneumatic Tube Transport System, 426
special units, 426
- furosemide, 110, 741, 759
protocol, 627
- GABA. *See* gamma-aminobutyric acid
- gamma-aminobutyric acid (GABA), 196, 205
- gastroenteritis, 481
- gastroenterologists, 512
- gastrointestinal bleeding
clinical protocols, 525–526
discharge criteria, 526
disposition criteria, 526
exclusion criteria, 525
inclusion criteria, 525
inpatient admission, 526
observation unit interventions, 525
order sets, 638–640
medications, 640–652
timeframe, 526
- gastrointestinal studies, 732
- gastroparesis, 310
- GCS. *See* Glasgow Coma Scale
- GDO. *See* Goal Directed Outcomes
- gender, readmissions and, 81
- general trauma
medications for, 724–725
order sets, 725
- generalized seizures, 201
- Geneva risk score, 168
- geriatric patients, 304, 501–502
acute abdominal pain in, 306
age-related observation, 483
discussion, 483
altered mental status, 305
comorbidities in, 483
costs of, 483–484
in EDOU, 483
evidence basis, 486–501
exclusion criteria, 305
falls in, 304
fractures in, 304
inclusions, 304
LOS for, 483
management, 304–305
mobility in, 304–305
orthostatic instability, 304–305
outcome, 304–305
in United States, 483–484
- geriatric services, 60
- German observation medicine
ACS in, 413
background, 413
chest pain units in, 413, 415
clinical need, 413
- Glasgow Coma Scale (GCS), 319, 320
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 144
- glucagon, 231, 233
- glycemic thresholds, 232
- Goal Directed Outcomes (GDO), 421–422
- Goal Directed Therapy, 421–422
- GOLD. *See* Global Initiative for Chronic Obstructive Lung Disease
- graded exercise testing, 124
- Graff, Louis, 403
- group homes, 343–344
- growth hormone, 231
- guaifenesin, 738
dextromethorphan and, 738
- Haemophilus influenzae*, 147
- HAP. *See* hospital acquired pneumonia
- HBV. *See* hepatitis B virus
- HCA. *See* health care assistant
- HCAP. *See* healthcare associated pneumonia
- HCC cardiac risk score tool, 90
- HCP. *See* healthcare professionals
- HCPCS. *See* Healthcare Common Procedure Coding System
- HCV. *See* hepatitis C virus
- head injury
analgesics for, 727–728
antiemetics for, 728
- evidence basis, 450–451, 463
intravenous fluids for, 728
order set, 728
medications, 727–728
pathophysiology, 320
- head pain, 46
- headaches
anatomy, 191–194
biochemical basis, 193–194
cellular basis of, 193–194
classifications, 190
clinical protocols, 527–528
definition, 189
discharge criteria, 528
disposition criteria, 527–528
exclusion criteria, 527
inclusion criteria, 527
inpatient admission, 527–528
medications for, 743–745
in observation unit, 197
observation unit interventions, 527
order sets, 641–642
medications, 642–643
pathophysiology of, 190–191
patient selection, 196–197
pharmacologic management, 197–198
prevalence of, 189
primary, 189–190
secondary, 189–190
sensitization, 194
with shunt, 646–647
specific therapy, 197
spinal, 643, 745
timeframe, 528
- Health and Human Services (HHS), 372–373
- health care
ACO and, 92
costs, 45
readmissions, 81–82
in United States, 45
spending, 484
utilization, 81–82
- health care assistant (HCA), 422
- Health Information and Portability Act (HIPPA), 49
- Health Information Management (HIM), 359
- Health Net, 370–371
- Health Resources Service Administration (HRSA), 339–341
- healthcare associated pneumonia (HCAP), 149
- Healthcare Common Procedure Coding System (HCPCS), GO378, 375
- Healthcare Financial Management Association, 355
- Healthcare Insurance Claim Number, 22

- healthcare professionals (HCP), 368
 - heart failure (HF)
 - ACE inhibitors for, 110–111
 - admission criteria, 111
 - appropriate therapy, 110
 - biomarkers, 108
 - clinical protocols, 528–529
 - discharge criteria, 111, 529
 - disposition, 528–529
 - diuretics for, 110
 - ejection fraction, 111
 - entry criteria, 109–110
 - exclusion criteria, 110, 528
 - history, 108
 - ICU and, 107
 - incidence of, 107
 - inclusion criteria, 528
 - inpatient admission, 528
 - LOS and, 107
 - Medicare and, 107
 - noninvasive bioimpedance technology, 108
 - observation unit interventions, 528
 - patient education, 111
 - physical examination, 108
 - presentation of, 107
 - radiographic findings, 108
 - therapy, 110–111
 - treatment goals, 108
 - heliox, 140
 - hematoma, 314
 - hematuria
 - clinical priorities, 529
 - discharge criteria, 529
 - disposition criteria, 529
 - exclusion criteria, 529
 - inclusion criteria, 529
 - inpatient admission, 529
 - observation unit interventions, 529
 - order sets, 647–649
 - medications, 648–649
 - hemoglobin and hematocrit (H&H), 287
 - hemolytic uremic syndrome, 255
 - hemophilia A, 253–254
 - hemophilia B, 254
 - hemothorax, 155
 - heparin, 511–512, 743
 - heparin-induced thrombocytopenia, 169
 - hepatitis B virus (HBV), 255
 - hepatitis C virus (HCV), 255
 - HF. *See* heart failure
 - HG. *See* hyperemesis gravidarum
 - H&H. *See* hemoglobin and hematocrit
 - HHS. *See* Health and Human Services; hyperosmolar hyperglycemic state
 - HICN *See* Healthcare Insurance Claim Number
 - Hill vs. Chynault*, 45
 - HIM. *See* Health Information Management
 - HINN. *See* Hospital Issue Notice of Non-Coverage
 - HIPPA. *See* Health Information and Portability Act
 - histamine H2 antagonist
 - medications, 604, 652
 - HIV. *See* human immunodeficiency virus
 - HMOs, 92–93
 - holding unit, 40–41
 - homatropine, 739
 - home visits, 82
 - hospital acquired pneumonia (HAP), 149
 - hospital administrators, 384
 - Hospital Issue Notice of Non-Coverage (HINN), 364, 375
 - Hospital Payment Monitoring Program (HPMP), 15, 19–20, 373
 - creation of, 373
 - hospital site of service, 28
 - hospitalist, 590
 - in observation medicine, 64
 - role of, 64
 - routines and, 64
 - hospitalization without admission, 21
 - housekeeping, 39
 - HPMP. *See* Hospital Payment Monitoring Program
 - HRSA. *See* Health Resources Service Administration
 - human immunodeficiency virus (HIV), 255
 - Humana, 370–371
 - hybrid units, 3–4
 - hydralazine, 741
 - hydrochlorothiazide, 741
 - hydrocodone, 313, 753
 - homatropine and, 739
 - order sets, 734
 - pharmacokinetic properties, 313
 - hydromorphone, 313, 753
 - order sets, 734
 - pharmacokinetic properties, 313
 - hydroxyzine, 756
 - order sets, 737
 - hyperbilirubinemia, 480
 - hypercalcemia, 238–239
 - clinical protocols, 523–524
 - management, 239
 - treatment, 238–239
 - hyperemesis gravidarum (HG), 289
 - characteristics, 289
 - clinical protocol, 529–530
 - discharge criteria, 530
 - disposition criteria, 530
 - exclusion criteria, 529–530
 - inclusion criteria, 529
 - management, 290
 - observation unit interventions, 530
 - order sets, 650–652
 - medications, 651–652
 - patient criteria, 289
 - symptoms, 289
- hyperglycemia, 73, 81
 - clinical presentation, 225–226
 - clinical protocol, 530–531
 - discharge criteria, 531
 - disposition criteria, 531–546
 - exclusion criteria, 530
 - fluid replacement, 227
 - inclusion criteria, 530
 - inpatient admission, 531
 - insulin therapy, 227–228
 - new-onset diabetics, 228
 - observation unit, 226–228
 - observation unit interventions, 530
 - order sets, 650–658
 - outcome, 229
 - patient selection, 226
 - hyperkalemia, 236–237
 - clinical protocols, 523–524
 - management, 237
 - treatment, 236–237
 - hyperlipidemia, 185–186
 - hypermagnesemia, 240, 523–524
 - treatment, 240
 - hyponatremia
 - clinical protocols, 523–524
 - treatment, 241
 - hyperosmolar hyperglycemic state (HHS), 225
 - hyperphosphatemia, 242
 - treatment, 242
 - hyperpolarization, 204
 - hypertension
 - clinical protocols, 531
 - discharge criteria, 531
 - disposition, 531
 - exclusion criteria, 531
 - inclusion criteria, 531
 - inpatient admission, 531
 - observation unit interventions, 531
 - order sets, 655–658
 - cardiac medications, 656–658
 - TIA and, 185
 - hypocalcemia, 237
 - intravenous fluids, 706
 - treatment, 238
 - hypoglycemia, 231
 - in diabetes, 232
 - glycemic thresholds, 232
 - observation unit, 233
 - order set, 659
 - pathophysiology, 231–232
 - patient selection, 232

Index

- hypoglycemia (cont.)
 risk factors, 231
hypokalemia, 235–236
 management, 236
 oral replacement, 708
 order sets, 707–708
 electrolyte replacements, 708
 symptoms, 235–236
 treatment, 235
hypomagnesemia, 239
 electrolyte replacements, 710
 intravenous fluids, 710
 oral replacement, 710
 order sets, 709–710
 treatment, 239–240
hyponatremia, 81, 240
 treatment, 241
hypophosphatemia, 241
 electrolyte replacement, 712
 intravenous fluids, 712
 oral replacement, 712
 order sets, 710–712
 treatment, 241
hypoxia, 146–147

IBD. *See* inflammatory bowel disease
ibuprofen, 313, 753
 order sets, 734
ICD. *See* International Classification of Diseases
ICD-9-CM, 19, 372 *See*
 International Classification of Diseases 9th revision
ICD-10-CM, 19, 359 *See*
 International Classification of Diseases 10th revision
ICU. *See* intensive care unit
idiopathic thrombocytopenic purpura (ITP), 255
IDSA. *See* Infectious Diseases Society of America
IME. *See* indirect medical education
Imitrex, 643, 646
inclusion criteria. *See also* admission criteria; exclusion criteria
 abdominal pain, 309, 514
 AF, 118–119, 517
 age-related observation, 477–506
 allergic reaction, 514
 altered mental status, 305, 515
 angioedema, 514
 apical pneumothoraces, 548
 asthma, 138–140, 516
 Australasian observation wards, 406–407
 back pain, 518
 cellulitis, 518
 central nervous system shunt, 222
 chest pain, 100, 519
 clinical protocols, 511
 COPD, 520
 dehydration, 272, 521
 dengue fever, 565
 DVT, 162
 EDOU, 73
 electrolyte abnormalities, 523
 extended observation, 73
 extremity infections, 524
 falls, 304
 gastrointestinal bleeding, 525
 generic protocols, 526
 geriatric observation medicine, 304
 headaches, 527
 heart failure, 528
 hematuria, 529
 HG, 529
 hyperglycemia, 530
 hypertension, 531
 PE, 162
 PSP, 155, 546
 rim pneumothoraces, 551
 seizures, 209
 syncope, 123
 trauma, 318–319
 UTI, 281
 vertigo, 522
independent review organizations (IROs), 379
indirect medical education (IME), 18–19
infectious disease patients
 background, 580
 discussion, 580–581
 objectives, 580
 policy, 580
Infectious Diseases Society of America (IDSA), 259, 513
inflammatory bowel disease (IBD), 252
 abdominal pain in, 310
inflammatory soup, 194–195
inhalers, 606, 612, 631, 759
inhibitory neurotransmitters, 205
in-hospital surge, 339
inositol triphosphate (IP3), 204–206
inpatient admission, 16–17. *See also*
 admission criteria
 abdominal pain, 514
 AF, 517
 allergic reaction, 515
 altered mental status, 516
 angioedema, 515
 asthma, 517
 back pain, 518
 cellulitis, 519
 COPD, 521
 dehydration, 522
 dengue fever, 565
 documentation checklist, 13
 electrolyte abnormalities, 523
 extremity infections, 525
 gastrointestinal bleeding, 526
 generic protocols, 527
 headaches, 527–528
 heart failure, 528
 hematuria, 529
 hyperglycemia, 531
 hypertension, 531
 medical necessity screening tools, 17
 Medicare Part A, 21
 observation and, 17–18
 observation usage rate and, 27–28
 threshold for, 27–28
 vertigo, 522
inpatient beds, 38
Inpatient Prospective Payment System (IPSS), 16
 defining, 18–19
 DRG in, 18–19
 observation and, 19
 reimbursement, 19–20
inpatient status, 363
inpatient stays, 766–767
inpatient supplies, 40
inpatient units, 39
INR. *See* international normalized ratio
insulin therapy, 636
 diabetes order set, 636
 hyperglycemia, 227–228
 sliding scale coverage, 636–637
insurance companies, 43
Integrated Output Code Editor (I/OCE), 360–361
intensity of service (IS), 17, 19
intensive care unit (ICU)
 HF and, 107
 readmissions, 79–81
intensive managerial review, 28–29
inter hospital surge, 339
International Classification of Diseases (ICD), 19
International Classification of Diseases (ICD) 9th revision (ICD-9-CM), 19
International Classification of Diseases (ICD) 10th revision (ICD-10-CM), 19
international normalized ratio (INR), 161, 167–169, 175, 252–253
interneurons, 205
InterQual, 17, 76–77, 89
 CMS licensing of, 370
 history of, 370
 for pain management, 315
 Severity of Illness criteria, 315–316
intrapreneurship, 93
intravenous fluids
 antibiotics, 612, 620, 761
 for head injury, 728
 hypocalcemia, 706
 hypomagnesemia, 710

- hypophosphatemia, 712
- order sets, 708, 710, 729
- intravenous unfractionated heparin, 160
- intravenous vitamin K, 175
- intussusception, 480
 - pediatric patients, 481
- I/OCE. *See* Integrated Output Code Editor
- ion channels, 202–203
- IP3. *See* inositol triphosphate
- ipratropium bromide, 140, 146, 740, 759
- IPSS. *See* Inpatient Prospective Payment System
- IROs. *See* independent review organizations
- IS. *See* intensity of service
- isolated chest injury order set, 702
 - medications, 615–702
- Italian observation medicine, 417–419
 - admission conditions, 419
 - NHS in, 418
 - settings, 419
 - states in, 419
 - structural point of view, 419
- Italian Presidential Decree of March 27th, 1992, 418
- ITP. *See* idiopathic thrombocytopenic purpura
- IV medications, 40
- JCAHO. *See* Joint Commission of Healthcare Organizations
- joint commission, 339
- Joint Commission of Healthcare Organizations (JCAHO), 49
- kallikrein inhibitor, 606
- ketamine, 140
- ketoacidosis, 46
- ketorolac, 277
- kidney injury, 81
- kidney stones
 - CT, 276
 - differential diagnosis, 277
 - discussion, 274
 - history, 275
 - imaging, 275–277
 - management, 277
 - medical therapy, 277
 - pathophysiology, 274
 - patient criteria, 277
 - physical examination, 275
 - special considerations, 277–278
 - ultrasound, 276–277
- kidney/ureter/bladder (KUB) radiography, 277
- Klebsiella*, 280
- KUB radiography. *See* kidney/ureter/bladder radiography
- laboratory department, patient recognition, 37
- Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC), 258
- laboratory test order sets, 730–732
- lansoprazole, 745, 759
- Latrodectus mactans* envenomation toxicology
 - admission criteria, 328
 - contraindications to admission, 328
- laxatives, 746–747
- LC. *See* locus coeruleus
- LCDs. *See* Local Coverage Determinants
- leadership
 - development of, 23–24
 - EDOU, 33
- lean initiatives, 48
- legal issues, 45
- length of stay (LOS), 19, 154, 370, 391
 - average, 58
 - chest pain and, 98–99
 - extended observation, 73
 - geriatric patients, 483
 - HF, 107
 - in New Zealand observation medicine, 409
 - PE, 165
 - pediatric observation, 294, 296
 - for pediatric patients, 482
 - readmissions, 79–81
- leukotriene modifiers, 140
- levalbuterol, 146–147
- levofloxacin, 151, 286
 - order sets, 736
- Lexi-Comp, 513
- Lexiscan, 127–129
- licensed providers, 6
- lidocaine, 739
- ligand-gated, 202–203
- LMRPs. *See* Local Medical Review Policies
- LMWH. *See* low-molecular-weight heparin
- Local Coverage Determinants (LCDs), 371–372
- Local Medical Review Policies (LMRPs), 371–372
- locus coeruleus (LC), 193
- long length of stay unit metrics, 51
- loratadine, 740, 758
- lorazepam, 757
 - order sets, 739
- LOS. *See* length of stay
- lovastatin, 742
- low-molecular-weight heparin (LMWH), 160, 169, 703–704, 743
- LP. *See* lumbar puncture
- LRINEC. *See* Laboratory Risk Indicator for Necrotizing Fasciitis
- lumbar puncture (LP), 197
- MACs. *See* Medicare administrative contractors
- MADFOCS scale, 334
- magnesium, 744
 - electrolyte abnormalities, 239
 - nomogram, 627–628
- magnesium citrate, 746
- magnesium hydroxide, 746
- magnetic resonance angiography (MRA), 183
- magnetic resonance imaging (MRI), 60, 372, 413–415, 750, 764
 - order sets, 695
 - TIA, 183
- major depression, 333
- managed care healthcare coverage programs, 370–371
- mandatory steroids, 481–482
- Marfan’s syndrome, 153
- mast cell modifiers, 140
- MCCs. *See* Medical Coordination Centers
- MCD. *See* Medicare Coverage Database
- McKesson, 17
- mechanical falls, 320
- MEDCAC. *See* Medicare Evidence Development & Coverage Advisory Committee
- Medicaid, 82
 - denied claims, 378
 - history of, 370
- Medical Benefit Policy Manual, 374
- medical clearance, 332
 - alcohol and, 337
 - components of, 336
 - psychiatric patients, 337
- Medical Coordination Centers (MCCs), 339
- medical director
 - additional qualifications, 582
 - background, 581
 - discussion, 582
 - job description, 581–582
 - licensing, 582
 - objectives, 581
 - training, 582
- medical malpractice, 45
- medical necessity, 88–90
 - AMA on, 371
 - coding, 386–387
 - definition, 371
 - denials, 380, 388–389
 - Emergency Physician in, 380
 - future directions in, 389
 - guidelines, 386
 - observation care and, 374–376

Index

- medical necessity (cont.)
 payment, 386–387
 physician considerations in, 388
medical necessity screening tools, 17
medical records, 357
Medicare, 11
 on ACOs, 93
 coverage loopholes, 767
 coverage problems, 767
 criteria, 370
 denied claims, 378
 DOJ on, 374
 facility reimbursement rates, 360–361
 Fifth Level appeal, 379
 finances of, 77
 Fourth Level appeal, 379
 general rules, 355–356
 HF and, 107
 history of, 370
 maximal reimbursement, 395
 observation coverage, 375
 Outpatient Code Editor, 387
 payment accuracy, 19–20
 payment error rates, 20
 physician documentation, 348, 353
 modifiers, 353–354
 protection of, 19–20
 readmissions and, 78
 reforms, 21
 sample reimbursements, 353–354
 Second Level review, 379
 for SNF, 767
 in stakeholder analysis, 383–384
 Third Level appeal, 379
Medicare administrative contractors (MACs), 15
 claims appeals, 378
 role of, 365
 work plans, 373–374
Medicare Coverage Database (MCD), 372
Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), 372
Medicare Inpatient Prospective Payment System (MIPPS), 395
Medicare Integrity Contractor, 22
Medicare Part A
 coverage under, 19
 deductible, 21
 inpatient admission, 21
Medicare Part B
 coverage under, 19
 outpatient claim, 376
Medicare Payment Advisory Commission (MedPAC), 11
Medicare Quality Improvement Organization, 374
MedPAC. *See* Medicare Payment Advisory Commission
Medicare Severity Adjusted – DRG, 14
MEMS. *See* Modular Emergency Medical System
Meniere’s disease, 214–215
metabotropic receptors, 204–206
methicillin resistant Staphylococcal (MRSA) infections, 257
 community acquired, 257–258
 prevention of recurrent, 261
methylprednisolone, 290, 742, 744, 758–759
metoclopramide, 737
metoprolol, 741
metrics
 background, 582
 clinical, 583
 discussion, 583–584
 objectives, 582–583
 pediatric observation, 584
 policy, 583
 QI, 583
MI. *See* myocardial infarction
MIC *see* Medicare Integrity Contractor
midlevel provider staffing, 39
 background, 584
 coverage, 5–6, 33–34
 discussion, 585
 objectives, 584
 policy, 584
 staffing ratios, 39
migraine, 189, 646
 anatomy, 191–194
 pathophysiology of, 191
 theories on, 191
Milliman care guidelines, 17, 76–77
MIPPS. *See* Medicare Inpatient Prospective Payment System
missed diagnosis rate, 27
 threshold for observation, 88
mission statement
 background, 585
 discussion, 585
 objectives, 585
 policy, 585
mobility, 304–305
mOBRI. *See* Modified Outpatient Bleeding Risk Index
Modified Outpatient Bleeding Risk Index (mOBRI), 174
Modified Pre-Verbal, Early Verbal Pediatric Pain Scale (M-PEPPS), 312
Modular Emergency Medical System (MEMS), 340–341
Moraxella catarrhalis, 147
morning blood draws, 4
morphine, 277, 313, 753–754
 order sets, 734–735
 pharmacokinetic properties, 313
motor vehicle collisions (MVC), 319
M-PEPPS. *See* Modified Pre-Verbal, Early Verbal Pediatric Pain Scale
MPI. *See* myocardial perfusion imaging
MRA. *See* magnetic resonance angiography
MRI. *See* magnetic resonance imaging
MRSA infections. *See* methicillin resistant Staphylococcal infections
MS. *See* multiple sclerosis
MS-DRS *See* Medicare Severity Adjusted – DRG
multi-disciplinary treatment team, 367
multiple sclerosis (MS), 214–215
MVC. *See* motor vehicle collisions
myocardial infarction (MI), 78, 88, 127, 520
 observation units and, 98–99
myocardial perfusion imaging (MPI), 103, 128–130
 stress, 131
myoclonic, 201
myoglobin, 102

NA. *See* needle aspiration
naloxone, 327
National Center for Health Statistics (NCHS), 19
National Correct Coding Initiative (NCCI), 372
National Coverage Analyses (NCAs), 372
National Coverage Determinations (NCDs), 371–372
 definition, 371
National Disaster Medical System (NDMS), 343
National Government Services, 373–374
National Health Service (NHS), 95
 in Italian observation medicine, 418
National Hospital Ambulatory Medical Care Survey (NHAMCS), 382
National Incident Management System (NIMS), 341
National Institute of Health (NIH), 190
National Quality Forum (NQF), 78, 367
 key measures, 368–369
National Strategy for Quality Improvement in Health Care
 goals of, 366
 priorities, 366

- National Uniform Billing Committee (NUBC), 376
- NCAs. *See* National Coverage Analyses
- NCCI. *See* National Correct Coding Initiative
- NCDs. *See* National Coverage Determinants
- NCHS. *See* National Center for Health Statistics
- NDMS. *See* National Disaster Medical System
- needle aspiration (NA), 154
- NEHC. *See* Neighborhood Emergency Help Center
- Neighborhood Emergency Help Center (NEHC), 340–341
- neurokinin A, 193
- neuroleptics toxicology admission criteria, 327 contraindications to admission, 327 discharge criteria, 328 management, 327 neurologic studies, 732 neuron, 202–203 neuronal excitability, 206–207 neuronal networks, 205 neuropeptides, 193 neurotransmitters, 193 excitatory, 204–205 inhibitory, 205 neurotransmitters inhibitory, 205
- New England Journal of Medicine, 21
- New York Heart Association (NYHA), 108
- New Zealand observation medicine case example, 409–410 LOS in, 409 national overview, 409 overcrowding, 409 patient admission, 409–410
- new-onset diabetics, 228
- NHAMCS. *See* National Hospital Ambulatory Medical Care Survey
- NHS. *See* National Health Service
- NIH. *See* National Institute of Health
- NIMS. *See* National Incident Management System
- NIPPV. *See* noninvasive positive pressure ventilation
- nitrates, 131
- nitric oxide (NO), 193
- nitroglycerin, 511–512, 520
- NIV. *See* noninvasive ventilation
- N-methyl-D-aspartate (NMDA), 195
- NO. *See* nitric oxide
- nociceptive fibers, 193–194
- nonbenzodiazepine hypnotics, 739–740
- non-contrast CT brain imaging, 182–183
- noninvasive bioimpedance technology, 108
- noninvasive positive pressure ventilation (NIPPV), 147
- noninvasive ventilation (NIV), 405
- non-physician practioner (NPP), 356
- notification of beneficiary, 20
- NQF. *See* National Quality Forum
- NPP. *See* non-physician practitioner
- NSAIDs, 247–248, 277, 313
- NSTEMI, 413–415
- N-terminal prohormone (NT-proBNP), 108
- NUBC. *See* National Uniform Billing Committee
- nuclear stress test, 128–130
- nucleus raphe magnus, 193
- nurses, 589 charge additional requirements of, 572 certification, 572 job description, 571 objectives, 571 reporting structure, 572 training, 571 clinical care pathways, 31–32 EDOU, 33 longevity, 5 manager additional qualifications, 586 background, 585 discussion, 586 job description, 585–586 licensure, 586 of observation unit, 42 reporting structure, 586 roll of, 42 training, 586 mindset, 37 models, 33–34 nursing documentation background, 577–578 discussion, 578 objectives, 578 reimbursement, 579 training, 578 nursing interventions in abdominal pain order set, 602 in AF order sets, 614 angioedema order sets, 605 nursing responsibilities background, 588 discussion, 589 disposition, 577 documentation, 589 objectives, 588 patient care, 588–589 patient satisfaction, 5 ratios, 4–5, 33–34, 38 scope of care background, 586–587 diagnostics, 587 discussion, 587–588 monitoring, 587 objectives, 587 policy, 587 procedures, 587 standard, 587 staffing clinical care pathways, 31–32 ratios, 4–5, 38 in stakeholder analysis, 384 training, 31–32
- NYHA. *See* New York Heart Association
- nystagmus, 213–215
- obesity, 81
- observation. *See also* pediatric observation abdominal pain, 265–266 AF, 119 anticoagulation, 177 complex, 12–15 as correct level of care, 27–28 defining, 2 diagnostic testing in, 512 ending, 375 evidence basis, 430–431 abdominal pain, 449–450, 462–463 abdominal trauma, 454–455 AF, 461–462 asthma, 445–447 cellulitis, 454 chest pain, 430–431, 460 congestive heart failure, 451–454 COPD, 456 criteria for, 471 critical questions, 468, 472 DVT, 460 ED efficiency, 457–458 future research, 468 head injury, 450–451, 463 methodology, 431 pneumonia, 456 results, 431–467 SCD, 462 summary, 466–468 syncope, 447–449 TIA, 460 toxicology, 455–456, 463 extended, 12–15 comprehensive teams, 77 cost effectiveness, 76 exclusion criteria, 73 financial concerns, 77 inclusion criteria, 73

Index

- observation (cont.)
 - LOS, 73
 - management, 73–74
 - pathophysiology, 73
 - patient discharge, 76
 - staff, 77
 - trends towards, 76
 - unit flow, 76–77
 - increased usage of, 382
 - inpatient admission criteria and, 17–18
 - IPSS, 19
 - Medicare
 - coverage, 375
 - sample reimbursements, 353–354
 - as mindset, 37
 - mislabeling, 12–13
 - in pain management, 315–316
 - as payment category, 363–364
 - PE, 169–170
 - as process, 4
 - SCD protocol, 247
 - simple, 12–15
 - stroke, 185
 - threshold, 27
 - TIA, 181–182
 - trends in, 382
 - typical times associated with, 352
 - VOC protocol, 247
- observation medicine. *See also specific countries*
- ACOs and, 93
 - AMUs and, 95–96
 - billing, 20–21
 - community hospital perspective, 58–59
 - culture, 407
 - curriculum, 66
 - education, 66–67
 - introduction of, 66
 - PGY-1, 66
 - PGY-2, 66
 - required rotations, 66–67
 - EM and, 68
 - expanding roles of, 72
 - fellowships in, 68
 - hospitalist and, 64
 - importance of, 48
 - lectures on, 68
 - medical necessity and, 374–376
 - observation status and, 766–767
 - origins of, 62
 - readmissions and, 83
 - training, 66–67
 - in urban community hospital, 60
- observation unit
- ACOs and, 93–94
 - administration of, 42
 - advantages of, 590–591
 - alternative terms for, 512
 - ancillary testing, 394
 - asthma treatment in, 139
 - bathroom facilities, 39
 - benchmarks, 8
 - benefits of, 512
 - business plan, 8–10
 - cardiac patients in, 40
 - census, 40
 - chest pain, 31, 100–101
 - clinical benefits of, 8
 - closed, 3
 - common diagnosis in, 293
 - COPD management, 145–147
 - cost savings from, 479
 - CQI components, 48
 - cross coverage in, 5
 - data sets, 49
 - database
 - clinical information, 50
 - CQI, 49–50
 - custom, 50
 - data elements, 49–50
 - electronic records, 50
 - procedures in, 49
 - specialized, 50
 - time in, 49
 - deaths in, 483
 - design, 7, 30–32, 39, 292
 - designated, 2–3, 64
 - discharge criteria, 516, 522
 - documentation
 - CQI, 50–51
 - procedures, 50
 - treatments, 50
 - economical service, 29
 - ED differentiated from, 64
 - efficiencies in, 394–395
 - emergency setting, 108–109
 - equipment, 7, 39, 292
 - financial benefits of, 8
 - headaches in, 197
 - health care crisis and, 478–479
 - hybrid, 3–4, 294
 - hyperglycemia, 226–228
 - hypoglycemia, 233
 - indicators
 - benchmarks, 53–54
 - CQI, 53
 - outcome, 53
 - process, 53
 - rate-based, 53
 - sentinel event, 53
 - structural, 53
 - intensive managerial review, 28–29
 - interventions
 - abdominal pain, 514
 - AF, 517
 - allergic reaction, 515
 - altered mental status, 515–516
 - angioedema, 515
 - asthma, 516–517
 - back pain, 518
 - cellulitis, 519
 - chest pain, 519
 - COPD, 521
 - dehydration, 521–522
 - electrolyte abnormalities, 523
 - extremity infections, 524–525
 - gastrointestinal bleeding, 525
 - headaches, 527
 - heart failure, 528
 - hematuria, 529
 - HG, 530
 - hyperglycemia, 530
 - hypertension, 531
 - vertigo, 522
 - justifications for, 391
 - length of stay, 4
 - location, 4, 31
 - meetings, 53–54
 - metrics, 8, 51
 - acuity, 52
 - complaints, 52
 - ED metrics and, 52
 - long length of stay, 51
 - short length of stay, 51–52
 - MI and, 98–99
 - nurse manager of, 42
 - open, 3
 - pain management protocols, 316
 - patient
 - amenities, 39
 - color coding, 37–38
 - grouping, 38
 - log, 54
 - placement, 37–38
 - recognition, 37
 - safety, 8
 - patients
 - amenities, 39
 - care, 39, 588–589
 - color coding, 37–38
 - grouping, 38
 - log, 54
 - noncompliance, 81
 - placement, 37–38
 - recognition, 37
 - safety, 8
 - selection criteria, 258–260
 - in stakeholder analysis, 382–384
 - pediatric, 7–8
 - performance improvement, 8
 - personnel, 30–31
 - costs of, 31
 - efficiency and, 31
 - physician coverage, 38–39, 76
 - physician medical director of, 41–42
 - pitfalls, 41
 - process, 30
 - protocol driven, 2–3
 - proximity, 30
 - quality experience, 8

- reimbursement, 389
- resource utilization, 72
- room size, 31
- rotation curriculum, 66
- seizures, 208–209
- size of, 7–8
 - estimation, 31
- SSTIs, 259–260
- supplies, 7, 39, 292
- tailoring, 512
- technology in, 39
- telephone in, 39
- television in, 39
- TIA in, 182
- time lag in, 40
- toileting in, 39
- toxicology, 323
- types of, 2–3, 30
- Observation Unit Meeting, 40
- observation usage rate, 28
 - chest pain, 89
 - inpatient admission and, 27–28
 - threshold for admission, 89
- observational status, 366, 368
 - changes in, 17–18
 - defining, 766
 - information sheets, 21
 - observation medicine and, 766–767
- OCE. *See* Outpatient Code Editor
- octreotide, 233
- OESIL. *See* Osservatorio Epidemiologicosulla Sincopenel Lazio
- Office of Inspector General (OIG), 21, 361, 382, 766
 - annual work plan, 372–373
 - improper payment
 - determinations in, 374
- ofloxacin, 286
- OIG. *See* Office of Inspector General
- omeprazole, 745, 759–760
- ondansetron, 290, 756–757
 - order sets, 737
- one-day inpatient hospital stays, 20
- OP measures. *See* outpatient measures
- open unit, 3
- opioids, 198, 245, 646, 745, 761
 - in pain control, 246, 313
 - for SCD, 246
 - toxicology
 - admission criteria, 326
 - contraindications to admission, 327
 - discharge criteria, 327
 - management, 327
 - for VOC, 246
- OPPS. *See* Outpatient Prospective Payment
- oral antibiotics, 612, 620, 631
- oral replacement, 712
- order sets, 513
 - abdominal pain
 - allergies in, 602–603
 - medications, 603–604
 - nursing interventions in, 602
 - respiratory interventions in, 603
 - vital signs in, 602
 - abdominal trauma, 713–715
 - medications, 714–715
 - acetaminophen, 733, 735
 - acute bronchitis, 511
 - adult generic, 748–751
 - advantages of, 513, 761
- AF
 - cardiac medications, 615
 - nursing interventions, 614
 - respiratory interventions, 614
 - vital signs, 613
- altered level of consciousness, 608–610 (*See also* altered mental status)
- altered mental status, 608–610
 - medications for, 609–610
- amoxicillin, 735
- ampicillin, 735
- analgesics, 733–735
- angioedema, 604–605
 - nursing interventions, 605
 - respiratory interventions, 605
- antibiotic therapy, 735–737
- antiemetics, 737–738
- antipyretics, 733–735
- antitussives, 738–739
- aspirin, 733
- asthma, 611–613
 - medications, 612–613
- azithromycin, 736
- back pain, 616–618
 - medications, 617–618
- benzodiazepines, 739
- cardiac medications, 740–741
- cardiac studies, 732
- cefazolin, 736
- ceftriaxone, 736
- cellulitis, 619–621
 - medications, 620–621
- cephalexin, 736
- chest pain, 622–624
 - cardiac medications, 623–624
- chest trauma, 615–702
- chronic obstructive pulmonary disease, 630–632
- ciprofloxacin, 736
- clindamycin, 736
- congestive heart failure, 625–629
 - cardiac medications, 626–628
 - cardiac studies, 626
- COPD, 630–632
 - medications, 630–632
- CT, 672
- dehydration, 633–635
 - medications, 634–635
- design of, 513
- diabetes, 636–637
 - antidiabetic agents, 637
 - insulin, 636
- dosages in, 513
- drug listings in, 513
- DVT, 742–743
- electrolyte abnormalities, 705–706
- extremity trauma, 720–722
- fentanyl, 733–734
- gastrointestinal bleeding, 638–640
 - medications, 640–652
- gastrointestinal studies, 732
- general trauma, 725
- head injury, 728
 - medications, 727–728
- headaches, 641–642
 - medications, 642–643
 - with shunts, 646–647
- heart failure, 625–629
- hematuria, 647–649
 - medications, 648–649
- HG, 650–652
 - medications, 651–652
- hydrocodone, 734
- hydromorphone, 734
- hydroxyzine, 737
- hyperemesis gravidarum, 650–652
- hyperglycemia, 650–658
- hypertension, 655–658
 - cardiac medications, 656–658
- hypoglycemia, 659
- hypokalemia, 707–708
 - electrolyte replacements, 708
- hypomagnesemia, 709–710
- hypophosphatemia, 710–712
- ibuprofen, 734
- intravenous fluids, 708, 710, 729
- isolated chest injury, 702
 - medications, 615–702
- kidney stones, 660–662
- laboratory tests, 730–732
- levofloxacin, 736
- lorazepam, 739
- metoclopramide, 737
- modification of, 513
- morphine, 734–735
- MRI, 695
- neurologic studies, 732
- nonbenzodiazepine hypnotics, 739–740
- ondansetron, 737
- overdose, 610
- oxycodone, 735
- pediatric generic, 762–765
- pediatric medications, 752–760
- pelvic inflammatory disease (PID), 284

Index

- order sets (cont.)
 - penicillin G, 737
 - penicillin V, 737
 - peritonsillar abscess, 532
 - pharyngitis, 671–674
 - piperacillin, 737
 - plain X-rays, 671
 - pneumonia, 675–679
 - possibilities in, 513
 - prochlorperazine, 737–738
 - promethazine, 738
 - pulmonary studies, 732
 - pyelonephritis, 679–681
 - radiology tests, 671–695
 - rib fractures, 702
 - medications, 615–702
 - seizures, 682–685
 - sickle cell disease, 686–689
 - steroids, 742
 - sulfamethoxazole, 737
 - syncope, 690–691
 - temazepam, 739
 - Toradol, 735
 - tramadol, 735
 - transfusion, 692–693
 - transient ischemic attack, 694–696
 - triazolam, 739
 - trimethobenzamide, 738
 - trimethoprim, 737
 - urinary tract infection, 649
 - US, 672
 - vaginal bleeding, 287
 - vertigo, 522–523
 - VTE, 702–704
- organizational structure
 - background, 590
 - discussion, 590–591
 - objectives, 590
 - policy, 590
- orthostatic instability, 304–305
- orthostatic syncope, 122
- Osservatorio Epidemiologicosulla Sincopenel Lazio (OESIL), 121
- OU See observation unit
- outcome indicators, 53
- Outpatient Code Editor (OCE), 387
- outpatient (OP) measures, 395
- outpatient observation services
 - CMS manual on, 20
 - coverage of, 20
 - defined, 20
- Outpatient Prospective Payment (OPPS), 355, 386
- outpatient setting, 28
- outpatient visits, 373
- oxycodone, 313, 754
 - acetaminophen with, 735
 - order sets, 735
 - pharmacokinetic properties, 313
- oxygen, 140, 146–147
- pacemakers, 205
- PAG. See periaqueductal grey
- pain clinics, 313–314
- pain management. *See also*
 - abdominal pain; chest pain
 - acute low back pain, 314–315
 - assessment, 312
 - chronic, 315
 - chronic pain of malignancy, 315
 - criteria for observation, 315–316
 - in elderly population, 314
 - epidemiology, 312
 - InterQual in, 315
 - medications, 313
 - opioids in, 246, 313
 - OU protocols, 316
 - principles, 312
 - in special populations, 314
- pain pathophysiology
 - CNS in, 196
 - dorsal root ganglion in, 195
 - periphery, 195
 - spinal cord in, 195
- pain scale, 312
- pain specialists, 313–314
- palliative care, 411
- panic disorder, 333
- pantoprazole, 746, 760
- paroxysmal AF, 114–115
- partial seizures, 201
- pathophysiology
 - AF, 114–115
 - antiepileptic drugs, 206
 - epilepsy, 205–206
 - extended observation, 73
 - head injury, 320
 - of headaches, 190–191
 - hypoglycemia, 231–232
 - mechanical falls, 320
 - of migraine, 191
 - MVC, 319
- pain
 - CNS in, 196
 - dorsal root ganglion in, 195
 - periphery, 195
 - spinal cord in, 195
- pediatric patients, 291–292
- penetrating trauma, 320
- rib fractures, 319–320
- of seizures, 201–206
- trauma, 319
- Patient Placement Department, 76–77
- Patient Protection Affordable Care Act, 78, 92
- patients. *See also* geriatric patients;
pediatric patients
 - amenities, 39
 - care
 - assistants, 39
 - nursing responsibilities, 588–589
 - color coding, 37–38
 - grouping, 38
 - log, 54
 - noncompliance, 81
 - placement, 37–38
 - recognition, 37
 - cardio/pulmonary department, 37
 - laboratory department, 37
 - observation unit, 37
 - radiology department, 37
 - safety, 8
 - selection criteria, 258–260
 - in stakeholder analysis, 382–384
- payers, 10
 - double dipping, 387
 - in stakeholder analysis, 384
- Payment Error Prevention Program, 22
- PC. *See* pharmacological cardioversion
- PCI. *See* percutaneous coronary intervention
- PE. *See* pulmonary embolism
- pediatric ED, 40
 - increases in visits, 482
 - returns to, 295–296
- pediatric generic order set, 762–765
- pediatric observation
 - abdominal pain, 301–302
 - admission criteria, 302
 - characteristics, 296
 - children’s hospital, 300–302
 - clinical criteria, 302
 - in community hospital, 59
 - cost effective, 295
 - CQI, 292
 - design, 292–293
 - differences in, 292–293
 - ED and readmissions, 295–296
 - equipment, 292–293
 - functions of, 300–301
 - future of, 297
 - hospital admissions, 295
 - hybrid unit, 296
 - international perspective, 295
 - LOS, 294, 296
 - medications, 292–293
 - metrics, 584
 - parental satisfaction, 296
 - patient care quality, 295
 - patient satisfaction, 296
 - performance improvement, 292
 - physician satisfaction, 296
 - principles of, 292
 - supplies, 292–293
 - types of, 300–301
- pediatric patients, 291
 - adult patients compared to, 294
 - age-related observation results, 479–482
 - costs in, 479–482

- dehydration, 481
- discussion, 482–483
- morbidity in, 481
- readmission rates, 481
- reoccurrence rates, 481
- return visits, 481
- satisfaction, 482
- asthma in, 480
- background, 292
- barium enema, 481
- communication, 291
- croup in, 481–482
- developmental factors, 291–292
- evaluation of, 291
- evidence basis, 486–501
- gastroenteritis, 481
- intussusception, 481
- LOS for, 482
- medications order set, 752–760
- pathophysiology, 291–292
- psychosocial admissions, 482
- Peer Review Organizations, 373
- pelvic inflammatory disease (PID), 284
 - clinical diagnostic criteria, 284
 - diagnosis, 284–285
 - management, 286
 - oral treatment regimens, 285
 - parenteral treatment regimens, 285
 - prevalence of, 284
- penetrating trauma, 320
- penicillin G, 756
 - order sets, 737
- penicillin V, 756
 - order sets, 737
- PEPP (See Payment Error Prevention Program)
- PEPPER report, 9, 373, 388–389
 - access, 15–16
 - Compare Worksheet, 15
 - contents of, 14–15
 - defining, 14
 - on one-day inpatient hospital stays, 20
 - payment errors, 16
 - targeted areas in, 20
 - two-midnight rule and revision of, 16
 - uses of, 15
- peptic ulcer disease (PUD), 252
- percutaneous coronary intervention (PCI), 79–81
- Performance Improvement (PI), 89
 - components, 48
 - costs, 48
 - goals, 48
 - pediatric observation, 292
 - toolbox, 48
- periaqueductal grey (PAG), 193
- Persantine, 127–129
- PESI. *See* Pulmonary Embolism Severity Index
- pharmacologic stress agents, 127–129
- pharmacological cardioversion (PC), 115
- PHI *See* Protected Health Information
- phlebotomy, 31, 37–38
- phosphate, 241
- physical examination
 - HF and, 108
 - physician documentation, 351
 - psychiatric patients, 335–336
 - in seizures, 207
- physician coding
 - 99217-discharge, 350
 - 99218-initial observation, 350
 - 99219-initial observation, 350
 - 99220-initial observation, 350
 - 99224-subsequent observation, 350
 - 99225-subsequent observation, 350–351
 - 99226-subsequent observation, 349–351
 - 99234-observation, 349
 - 99235-observation, 349
 - 99236-observation, 349
 - reimbursement in, 359
 - scenarios, 349–351
 - summary of, 349–351
- coverage, 38–39
- documentation, 348
 - background, 579
 - comprehensive history, 351
 - critical care, 354
 - detailed history, 351
 - disposition, 579–580
 - justifying medical necessity in, 348
 - Medicare, 348, 353–354
 - objectives, 579
 - ongoing evaluation, 579
 - physical exam, 351
 - prolonged services, 352
 - reimbursement and, 356–357
 - requirements, 348–349, 351
 - summary of, 351
- EDOU, 33
- medical director, 41–42
- in medical necessity, 388
- mindset, 37
- reimbursement, 24–25
- responsibilities
 - background, 575
 - disposition, 575, 577
 - objectives, 575
 - ongoing management, 575
 - policy, 575
- staffing, 5
- ratios, 39
- in stakeholder analysis, 384
- supervising, 35
- PI. *See* Performance Improvement
- PICA. *See* posterior inferior cerebellar artery
- PID. *See* pelvic inflammatory disease
- piperacillin, 756
 - order sets, 737
- plain X-rays, 750, 764
 - order sets, 671
- Platelet Glycoprotein IIb/IIIa in Unstable Angina Using Integrilin Therapy (PURSUIT), 100
- platelets, 254–255
 - prophylactic transfusion, 254
 - thresholds, 254
- Pneumatic Tube Transport System, 426
- pneumonia, 40, 82
 - in emergency department, 149
 - evidence basis, 456
 - risk factors, 149–150
- pneumonia patient outcomes
 - research time (PORT), 150
- POA. *See* Present on Admission
- polyethylene glycol, 746–747, 760
- polymenorrhea, 287
- PORT. *See* pneumonia patient outcomes research time
- posterior inferior cerebellar artery (PICA), 220
- post-transfusion purpura (PTP), 255
- potassium, 624
 - abnormalities, 235
 - nomogram, 627–628
 - supplements, 623
- PPI. *See* proton pump inhibitors
- prednisolone, 742, 758
- prednisone, 742, 758
- Present on Admission (POA), 372
 - accuracy of, 373
- Press-Ganey scores, 6
- pretest probability
 - of CAD, 127–128
 - stress tests and, 127–128
- PRIDE study, 108
- primary headache, 189–190
- primary seizures, 201
- primary spontaneous pneumothorax (PSP), 153–155
 - discharge criteria, 155–156
 - exclusion criteria, 155, 546
 - inclusion criteria, 155, 546
 - intervention, 155–156
 - large, 154
 - management, 155–156, 548
 - presentation of, 153
 - small, 153–154

Index

- process indicators, 53
- prochlorperazine, 757
 - order sets, 737–738
- Program for Evaluating Payment Patterns Electronic Reports 14
- prolonged services
 - physician documentation, 352
 - time thresholds, 352
- promethazine, 290, 757
 - codeine and, 738–739
 - order sets, 738
- Protected Health Information 22
- Proteus*, 280
- Policies – Administrative (See Administrative Policies)
- Protocols - Clinical (See clinical protocols)prothrombin time (PT), 161
- protocol driven unit, 2–3
- proton pump inhibitors (PPI), 268, 652, 745–746, 759–760
- provider liable, 364
- provocative stress test
 - chest pain and, 103
 - exercise, 103
- proximity of observation unit, 30
- Prudential, 370–371
- Pseudomonas aeruginosa*, 147, 280
- PSI, 150
- PSP. *See* primary spontaneous pneumothorax
- psychiatric patients, 332
 - in ED, 332
 - emergencies, 332–333
 - imaging in, 337
 - medical clearance, 337
 - medical illnesses simulating, 334
 - physical examination, 335–336
 - present illness history in, 335
 - routine testing, 336–337
- psychosocial admissions, 482
- PT, 161, 567. *See* prothrombin time
- PTP. *See* post-transfusion purpura
- PUD. *See* peptic ulcer disease
- pulmonary arterial bed, 165
- pulmonary embolism (PE), 98, 159, 165, 567
 - anticoagulation for, 169
 - diagnosis, 165–167
 - discharge criteria, 162
 - inclusion criteria, 162
 - LOS, 165
 - low-risk, 167–169
 - mortality, 165
 - observation care, 169–170
 - outcome, 163
 - patient selection, 169
 - risk stratification, 167–169
- Pulmonary Embolism Severity Index (PESI), 168
- pulmonary studies, 732
- PURSUIT. *See* Platelet Glycoprotein IIb/IIIa in Unstable Angina Using Integrilin Therapy
- pyelonephritis, 281
- QA. *See* quality assurance
- QCS. *See* Quick Confusion Scale
- QI. *See* quality improvement
- QIC. *See* Qualified Independent Contractor
- QIO. *See* Quality Improvement Organization
- Qualified Independent Contractor (QIC), 379
- quality assurance (QA), 73
- quality improvement (QI), 73
 - metrics, 583
- Quality Improvement Organization (QIO), 15, 373
 - CMS contracts with, 20
- quality of care, 365
- Quick Confusion Scale (QCS), 335
- RAC. *See* recovery audit contractor
- radiographic findings, 108
- radiology department, 37
- radiology studies
 - contrast allergy and, 747, 760–761
 - order studies, 671–695
- randomized clinical trials (RCTs), 24, 154
- Rapid Diagnostic and Treatment Unit (RDTU), 512
- Rapid Intense Observation Unit (RIO), 72
 - admission rates, 72–73
 - management, 72–73
- rate-based indicators, 53
- rattlesnake bites
 - allergic reaction, 556
 - CDU protocol, 563
 - clinical protocols, 556–558
 - consults, 557–558
 - contraindications, 560–562
 - diet, 556
 - discharge criteria, 558
 - disposition, 558
 - ED evaluation, 563
 - follow-up, 558
 - indications, 560
 - labs, 557
 - medications, 556–557
 - physician orders, 558–559
 - severity grading, 560
- RBC. *See* red blood cell
- RBRVS. *See* Resource Based Relative Value Scale
- RCTs. *See* randomized clinical trials
- RDTU. *See* Rapid Diagnostic and Treatment Unit
- readmissions
 - access to care and, 81–82
 - associated factors, 80
 - avoidable, 83
 - CMS rates, 78
 - costs of, 78
 - decreasing rates, 78, 83
 - demographic variables, 81
 - exercise and, 81
 - gender and, 81
 - health care utilization and, 81–82
 - hospital factors, 82
 - ICU, 79–81
 - individual factors, 81
 - injury and, 79
 - international perspective, 79
 - LOS, 79–81
 - Medicare and, 78
 - obesity and, 81
 - observation medicine and, 83
 - patient disease and, 79
 - patient noncompliance and, 81
 - in pediatric age-related observation, 481
 - pediatric observation and, 295–296
 - potential solutions, 82–83
 - problems with measuring, 79
 - reduction of, 79
 - report to Congress, 79
 - risk-standardized, 78
 - seven day, 20
 - smoking and, 81
 - socioeconomic factors, 81
 - 30-day, 78
 - unavoidable, 79
 - VHA rates, 78
- receptors, 204
- recovery audit contractor (RAC), 12, 14, 361, 374, 382
 - claims reviews of, 374
 - role of, 365
 - in tertiary care hospitals, 63
- red blood cell (RBC), 275
 - transfusion, 250–251
 - recommendations, 250–251
- Red Book of Pediatrics, 513
- re-expansion pulmonary edema (RPE), 155
- regadenoson, 127–129
- regulatory billing, 31–32
- reimbursement
 - best practice and, 356–357
 - composite, 360–361
 - database, 575
 - documentation requirements, 356–357
 - facility, 24–25, 360–361
 - Medicare rates, 360–361
 - IPSS, 19–20

- maximal, 395
 - nursing documentation, 579
 - observation unit, 389
 - physician documentation and, 356–357
 - in revenue cycle management, 356
 - billing, 359–360
 - charging, 357–359
 - physician coding, 359
 - registration, 356
 - sample, 353–354
 - Relative Value Unit (RVU), 352–353
 - combined, 353
 - comparison of, 353
 - for subsequent observation, 353
 - Relative Value Update Committee (RUC), 352
 - RE-LY trial, 116–117
 - renal colic, 275
 - renal failure, 520
 - reperfusion therapy, 98
 - Resource Based Relative Value Scale (RBRVS), 352–353
 - formula, 352–353
 - Resource Utilization Group 22
 - respiratory interventions
 - in abdominal pain order set, 603
 - AF order sets, 614
 - angioedema order sets, 605
 - revenue cycle management, 355
 - reimbursement in, 356
 - billing, 359–360
 - charging, 357–359
 - physician coding, 359
 - registration, 356
 - revised Geneva score, 165–166
 - rib fractures
 - order set, 702
 - medications, 615–702
 - pathophysiology, 319–320
 - right ventricular dysfunction (RVD), 167
 - rim pneumothoraces, 155
 - exclusion criteria, 551
 - inclusion criteria, 551
 - interventions, 551
 - RIO. *See* Rapid Intense Observation Unit
 - risk management
 - abdominal pain, 46
 - alcoholism, 46–47
 - approach, 46
 - asthma, 46
 - chest pain, 46
 - chest pain scores, 100
 - communication in, 44
 - cost-effectiveness, 45
 - data, 44
 - decreasing risk, 46
 - definition, 43
 - diabetes, 46
 - function of, 43–44
 - goals, 46
 - head pain, 46
 - high risk situations, 45–47
 - ketoacidosis, 46
 - legal issues, 45
 - new modes of, 43–44
 - quality assurance, 44
 - system redesign, 46
 - risk stratification, 90–91
 - ABCD2 TIA, 90
 - chest pain, 99–100
 - PE, 167–169
 - TIA, 180–181
 - UGIB, 268
 - Risk Stratification of Syncope in Emergency Department (ROSE), 121
 - risk-standardized readmission rates (RSRRs), 78
 - rivaroxaban, 160–161
 - Rockall system, 267–268
 - ROMICAT, 103
 - ROSE. *See* Risk Stratification of Syncope in Emergency Department
 - rosuvastatin, 742
 - RPE. *See* re-expansion pulmonary edema
 - RSRRs. *See* risk-standardized readmission rates
 - RUC. *See* Relative Value Update Committee
 - RUG *See* Resource Utilization Group
 - RVD. *See* right ventricular dysfunction
 - RVRVS. *See* Resource Based Relative Value Scale
 - RVU. *See* Relative Value Unit
 - SAEM. *See* Society for Academic Emergency Medicine
 - SAH. *See* subarachnoid hemorrhage
 - San Francisco Syncope Rule (SFSR), 121
 - Sant’Andrea Hospital, 419
 - scatter beds, 4, 12
 - SCD. *See* sickle cell disease
 - schizophrenia, 332–333
 - Second Level review, 378–379
 - denial letter, 379
 - Medicare, 379
 - secondary headache, 189–190
 - secondary seizures, 201
 - secretaries, 39
 - seizures
 - absence, 201
 - classifications, 201
 - definitions, 200–201
 - in ED, 200
 - exclusion criteria, 208
 - febrile, 200
 - generalized, 201
 - inclusion criteria, 209
 - observation unit management, 208–209
 - partial, 201
 - pathophysiology of, 201–206
 - patient evaluation, 207–208
 - patient selection, 208
 - physical examination in, 207
 - prevalence of, 200
 - primary, 201
 - secondary, 201
 - threshold, 209
- Seldinger technique, 154
- aftercare, 555
 - kit contents, 553–555
 - procedure, 553–555
- self-reporting, 337
- senior care crisis, 483–484
- sensitization
- central, 194–195
 - headaches, 194
- sentinel event indicators, 53
- seven day readmissions, 20
- severity of illness (SI), 17, 19, 363
- SFSR. *See* San Francisco Syncope Rule
- SHCN. *See* Special Health Care Needs
- short acting beta agonists, 146–147
- short length of stay metrics, 51–52
- short stay units (SSUs), 292, 480
- SI. *See* severity of illness
- sickle cell disease (SCD), 244, 251, 473
- adjunctive therapy, 247–248
 - admission criteria, 246–247
 - clinical pathway, 246
 - consults, 246–247
 - current management, 245
 - evidence basis, 462
 - individualized treatment regimens, 246
 - management goals, 245–248
 - observation protocol, 247
 - opioids for, 246
 - pathway metrics, 247
 - pitfalls in management, 248
 - in United Kingdom observation medicine, 422
- simethicone, 746
- simple observation, 12–15
- simvastatin, 742
- Singapore observation medicine
- asthma in, 405
 - challenges, 403
 - COPD in, 405
 - origins, 403
 - protocols, 403–404
 - role of, 405
 - staffing in, 403
 - unique features of, 404–405

Index

- single positron emission computed tomography (SPECT), 128–130
- six sigma, 48
- skilled nursing facility (SNF), 767
- sleeping pills, 757
- smoking
- cessation, 747
 - readmissions and, 81
- SNF. *See* skilled nursing facility
- social resources, 58–59
- Social Security Act of 1965, 370–371
- social workers, 411
- Society for Academic Emergency Medicine (SAEM), 23–24
- Society of Chest Pain Centers, 25, 32
- Society of Hospital Medicine, 5
- sodium, 240
- sodium polystyrene sulfonate (SPS), 237
- soft tissue infections (SSTIs), 257
- antibiotic therapy, 261
 - classification system, 259
 - clinical presentation, 257–258
 - conditions mimicking, 260
 - discharge criteria, 260–261
 - imaging, 258
 - laboratory evaluation, 258
 - management, 260
 - non-suppurative, 257
 - observation unit, 259–260
 - patient selection criteria, 258–260
 - transfer criteria, 260–261
- South Africa
- emergency center observation wards, 398–399
 - emergency medicine in, 398
- Special Health Care Needs (SHCN), 292
- special needs shelter, 343–344
- SPECT. *See* single positron emission computed tomography
- spinal cord, 192–193
- in pain pathophysiology, 195
- spinal headaches, 643, 745
- SPS. *See* sodium polystyrene sulfonate
- SSTIs. *See* soft tissue infections
- SSUs. *See* short stay units
- St. Thomas’ Hospital, 421
- staffing, 38–39. *See also specific staff*
- acute care, 28
 - additional personnel, 6–7
 - administrative, 7
 - advanced practice providers, 5–6
 - alternative care facilities, 341
 - ancillary, 31–32
 - background, 589
 - EDOU, 35
 - objectives, 589
 - policies, 589
 - CDU, 58–59
 - census, 40–41
 - clinical care pathways, 31–32
 - cost analysis, 41
 - evolution of, 24
 - flexible, 4
 - midlevel provider, 39
 - background, 584
 - coverage, 5–6, 33–34
 - discussion, 585
 - objectives, 584
 - policy, 584
 - staffing ratios, 39
 - models, 33–34
 - nurse staffing ratios, 4–5, 38
 - patient satisfaction, 5
 - physicians, 5
 - ratios, 39
 - pulling, 41
 - in Singapore observation medicine, 403
- stakeholder analysis
- APCs in, 384
 - business model, 382–384
 - hospital administrators in, 384
 - Medicare in, 383–384
 - nurses in, 384
 - patients in, 382–384
 - payers in, 384
 - physicians in, 384
- STEMI, 413–415
- ECG for, 101
- steroids, 742
- Strengths, Weaknesses, Opportunities, Threats (SWOT), 382
- Streptococcus pneumoniae*, 147
- stress cardiovascular magnetic resonance imaging, 130
- characteristics, 130
- stress echocardiogram, 130
- characteristics, 131
- stress electrocardiogram, 128
- stress myocardial perfusion imaging, 131
- stress tests, 38
- CTCA, 130
 - management, 131
 - nuclear, 128–130
 - outcome, 131
 - patient characteristics, 131
 - pharmacologic, 127–129
 - preparation for, 131
 - pretest probability, 127–128
 - types of, 128–130
 - in women, 130–131
- stroke
- anticoagulation for, 185
 - aspirin for, 184
 - clopidogrel for, 184
 - dipyridamole for, 184
 - following TIA, 181
 - medical management, 184
 - observation, 185
 - ticlopidine for, 184
- structural indicators, 53
- subarachnoid hemorrhage (SAH), 189
- subcutaneous calcitonin, 239
- subcutaneous vitamin K, 175
- substance abuse, 515–516
- substance P, 193
- sulbactam, 151, 735
- ampicillin with, 735, 755
- sulfamethoxazole, 756
- order sets, 737
- sulfonylureas toxicology
- admission criteria, 325
 - contraindications to admission, 325
 - discharge criteria, 326
 - management, 326
- sumatriptan, 744–745
- supervising physician, 35
- surgical emphysema, 155
- SWOT. *See* Strengths, Weaknesses, Opportunities, Threats
- synaptic transmission, 204–205
- syncope
- classification of, 122
 - CT of, 124
 - definition, 121
 - differential diagnosis, 121
 - echocardiography for, 124
 - electrocardiographic monitoring, 124
 - electrophysiology of, 124
 - etiologies, 122
 - evidence basis, 447–449
 - exclusion criteria, 123
 - graded exercise testing, 124
 - inclusion criteria, 123
 - management, 123
 - orthostatic, 122
 - outcomes, 124
 - pathophysiology, 122
 - tilt-table testing, 124
- systemic corticosteroids, 140
- TACO. *See* transfusion-associated circulatory overload
- Tax Relief and Health Care Act, 374
- tazobactam, 756
- TCC. *See* trigeminocervical complex
- technetium-99m, 103, 128–130
- TEE. *See* transesophageal echocardiography
- telemetry systems, 31, 101
- telephone
- follow-up phone calls, 82
 - lines, 39
 - in observation unit, 39
- television, 39
- temazepam, 739
- tension pneumothorax, 155

- tertiary care hospitals, 62
 - CMS and, 63
 - definition, 62–63
 - finances of, 63
 - optimal size of, 63
 - RAC in, 63
 - referral to, 62
- Texas Childrens Hospital, 301–302
- THA. *See* total hip arthroplasty
- thallium-201, 128–130
- theophylline, 140
- Third Level appeal, 379
- third party payers, 370–371
- thrombocytopenia, 169–170, 252
- thromboembolism, 116
- Thrombolysis in Myocardial Infarction (TIMI), 100, 103
- thrombotic thrombocytopenic purpura (TTP), 251–253, 255
- TIA. *See* transient ischemic attack
- ticlopidine, 184
- tilt-table testing, 124
- time, tincture of, 27
- time lag, 40
- TIMI. *See* Thrombolysis in Myocardial Infarction
- tincture of time, 27
- tinzaparin, 743
- tip on needle thoracocentesis, 549
- TKA. *See* total knee arthroplasty
- TMF Health Quality Institute, 373
- toileting, 39
- Toradol, 744, 754
 - order sets, 735
- total hip arthroplasty (THA), 78
- total knee arthroplasty (TKA), 78
- toxicology, 560
 - acetaminophen
 - admission criteria, 323–324
 - contraindications to admission, 323–324
 - discharge criteria, 324
 - management, 324
 - benzodiazepines
 - admission criteria, 324
 - contraindications to admission, 324
 - discharge criteria, 324
 - management, 324
 - reversal, 325
 - bupropion
 - admission criteria, 325
 - contraindications to admission, 325
 - discharge criteria, 325
 - management, 325
 - carbon monoxide
 - admission criteria, 326
 - contraindications to admission, 326
 - discharge criteria, 326
 - management, 326
 - crotalid envenomation
 - admission criteria, 328
 - antivenom, 329
 - contraindications to admission, 328
 - management, 328
 - ED visits from, 323
 - evidence basis, 455–456, 463
 - Latrodectus mactans* envenomation
 - admission criteria, 328
 - contraindications to admission, 328
 - neuroleptics
 - admission criteria, 327
 - contraindications to admission, 327
 - discharge criteria, 328
 - management, 327
 - opioids
 - admission criteria, 326
 - contraindications to admission, 327
 - discharge criteria, 327
 - management, 327
 - in OU, 323
 - sulfonylureas
 - admission criteria, 325
 - contraindications to admission, 325
 - discharge criteria, 326
 - management, 326
- Toyota production mode, 48
- training
 - case manager, 570
 - charge nurse, 571
 - medical director, 582
 - nurse, 31–32
 - nurse manager, 586
 - nursing documentation, 578
 - observation medicine, 66–67
- tramadol, 313, 754
 - order sets, 735
- transesophageal echocardiography (TEE), 116
- transfer to observation, 76–77
- transfusion reactions, 255, 640
- transfusion triggers, 250
- transfusion-associated circulatory overload (TACO), 255
- transient ischemic attack (TIA), 180, 212, 473
 - admission, 186
 - cardiac imaging, 183–184
 - carotid artery duplex ultrasound, 183
 - consultation, 186
 - CTA of, 183
 - definition, 180
 - diabetes and, 185
 - differential diagnosis, 182
 - discharge criteria, 186–187
 - disposition, 186
 - in ED, 182
 - evaluation of, 181
 - evidence basis, 460
 - follow-up, 187
 - hyperlipidemia and, 185–186
 - hypertension and, 185
 - MRA of, 183
 - MRI of, 183
 - non-contrast CT brain imaging, 182–183
 - observation, 181–182
 - in OU, 182
 - risk factors, 186
 - risk stratification, 180–181
 - stroke following, 181
 - surgical management, 185
 - symptoms, 181
 - vascular imaging, 183
 - workup, 182
- transitional care, 367
 - reengineering, 368–369
- transthoracic echocardiography (TTE), 184
- trauma, 318
 - diagnosis, 318
 - disposition after observation, 321
 - exclusion criteria, 319
 - inclusion criteria, 318–319
 - intervention, 320–321
 - management, 320–321
 - pathophysiology, 319
- triazolam, 739
- tricyclic antidepressants, 196
- trigemino-cervical complex (TCC), 191
- trigeminothalamic tract, 193
- trimethobenzamide, 757
 - order sets, 738
- trimethoprim, 756
 - order sets, 737
- troponin, 101–102
 - chest pain and, 102
- TTE. *See* transthoracic echocardiography
- TTP. *See* thrombotic thrombocytopenic purpura
- two-midnight rule, 11
 - background, 12
 - impact of, 13
 - PEPPER report revision and, 16
- UA. *See* unstable angina
- UB04 outpatient bill, 17–18
- UFH. *See* unfractionated heparin
- UGIB. *See* upper gastrointestinal bleeding
- ultrasound, 750, 764
 - compression, 159–160, 167
 - kidney stones, 276–277
 - order sets, 672

Index

- unfractionated heparin (UFH), 169
- unit coordinators, 589
- United Kingdom observation medicine
 - EMU in, 421
 - GDO in, 421–422
 - history of, 421
 - outcomes, 422–423
 - sickle cell disease in, 422
- United States
 - age-related observation in, 484
 - commercially available drugs in, 513
 - geriatric patients in, 483–484
 - health care in, 45
 - spending, 484
 - hospital savings in, 479
 - unstable angina (UA), 101
 - upper gastrointestinal bleeding (UGIB)
 - discussion, 267–268
 - exclusion criteria, 267
 - outcome, 268–269
 - patient criteria, 267
 - risk stratification, 268
- UR. *See* Utilization Review
- urban community hospital ED, 60
 - observation medicine in, 60
 - successful operation, 60
- urinalysis, 275
- urinary tract infection (UTI), 280
 - inclusions, 281
 - interventions, 281–282
 - management, 281–282
 - outcomes, 282
 - pathophysiology, 280–281
- urolithiasis, 274
- UTI. *See* urinary tract infection
- Utilization Committee, 17–18
- Utilization Review (UR), 89–90, 360, 367
 - early years of, 370
 - performing, 89
- vaginal bleeding, 287
 - management, 287
 - outcome, 287–288
 - patient criteria, 287
- valproate, 745
- VAP. *See* ventilator associated pneumonia
- vascular imaging, 183
- vaso-occlusive crisis (VOC), 244, 245, 244
 - adjunctive therapy, 247–248
 - admission criteria, 246–247
 - clinical pathway, 246
 - consults, 246–247
 - individualized treatment regimens, 246
 - management goals, 245–248
 - observation protocol, 247
 - opioids for, 246
 - pitfalls in management, 248
- VATS. *See* video-assisted thoracoscopic surgery
- venous thromboembolism (VTE), 159, 173
 - diagnosis, 159–160
 - discussion, 159–160
 - order set, 702–704
 - outcome, 163
 - symptoms, 159
 - treatment, 159–160
- ventilation-perfusion scintigraphy (V/Q scan), 166–167
- ventilator associated pneumonia (VAP), 149
- ventral posteromedial thalamic nucleus (VPM), 193
- vertigo
 - central causes, 218–220
 - clinical protocols, 522–523
 - differential diagnosis, 215–218
 - discharge criteria, 522–523
 - disposition criteria, 522–523
 - exclusion criteria, 522
 - inclusion criteria, 522
 - inpatient admission, 522
 - observation unit interventions, 522
 - timeframe, 523
 - vestibular causes of, 217
- Veterans Health Administrations (VHA), 78
- video-assisted thoracoscopic surgery (VATS), 155
- vital signs, 312
 - in abdominal pain order set, 602
 - in AF order sets, 613
- vitamin B6, 290
- vitamin K
 - antagonists, 615, 703
 - anticoagulation reversal with, 175
 - epoxide reductase, 175
 - intravenous, 175
 - oral administration, 175
 - reductase, 175
 - subcutaneous, 175
- vitamin K agonist (VKA), 160, 167–169
- vitamin K oxide reductase (VKOR), 174
- VKA. *See* vitamin K agonist
- VKOR. *See* vitamin K oxide reductase
- VOC. *See* vaso-occlusive crisis
- voltage-gated, 202–203
- vomiting, 271
 - clinical protocols, 521–522
- von Willebrand disease (vWD), 254
- von Willebrand factor (vWF), 253
- VPM. *See* ventral posteromedial thalamic nucleus
- V/Q scan. *See* ventilation-perfusion scintigraphy
- VTE. *See* venous thromboembolism
- vWD. *See* von Willebrand disease
- vWF. *See* von Willebrand factor
- waiting rooms, 43
- warfarin therapy, 116, 160, 252, 742–743
 - commercially distributed, 173–174
 - dose, 174
 - FFP and, 252
 - history of, 173
 - onset of, 174
 - pharmacology, 173–174
 - reversal, 252
- WBC. *See* white blood cell count
- WellPoint, 370–371
- Wells rule, 165–166
- Western Cape Package of Care, 400
- white blood cell count (WBC), 258, 275
- women, stress tests in, 130–131
- Y-model, 393–394
 - quality and cost focus of, 393
- zig-zag model of care, 394
- zolpidem, 739
- Zone Program Integrity Contractors, 22
- ZPIC. *See* Zone Program Integrity Contractors